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Cytokine profiles during cowpox virus (CPV) strain Brighton and vaccinia 
virus (VV) strain Western Reserve infections were characterized in intranasal (i.n.) and 
intraperitoneal (i .p.) models in BALB/c mice. The time-course of induction and effects 
of cidofovir treatment on interferon (IFN)-y, IFN-y inducible protein (IP)-1 0, 
interleukin (IL)-6, and monocyte chemoattractant protein (MCP)-1 were determined. 
The four models have distinct patterns of cytokine induction. CPV i.p. and VV i.n. 
infections showed increased induction throughout the time studied. CPV i.n. infection 
resulted in delayed induction of IFN-y and IP-1 0. Cytokine levels were fairly constant 
during VV i.p. infections. Cidofovir treatment (100 mglkg/day i.p. for 2 days) 
significantly reduced certain cytokine levels in the four models. Treatment did not 
affect IP-10 in the CPV i.n. model; IFN-y and IP-10 in the CPV i.p. model ; or IL-6, IP-
10, and MCP-1 in the VV i.p. model. Characterization ofcytokine responses has 
implications for understanding the immune responses and pathogeneses of viral 
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INTRODUCTION 
Smallpox is a deadly scourge that has invoked terror through the ages . With the 
global elimination of this viral pathogen from nature there are some individuals who no 
longer perceive it as a realistic threat. Only two locations worldwide (one in the 
United States and one in Russia) have stockpiles of smallpox, but it is possible that a 
terrorist group may have small quantities. These caches were initially ordered to be 
destroyed. However, it was decided to be prudent to maintain these stocks for potential 
research purposes. With routine vaccinations ceasing in the 1970's much of the 
world's population is left unprotected from a potential bioterrorist attack employing 
this menace. Although studies show that individuals vaccinated still maintain some 
protection from the disease many years after vaccination (Crotty et al., 2003 ; 
Hammarlund et al. , 2003), the potential for terrorists to use genetically modified 
smallpox would also render these individuals prone to infection. With a mortality of 
up to 30-40 percent and disfigurement for the survivors, smallpox is certainly a virus to 
be concerned about (Fenner et al., 1989). Furthermore, the World Health Organization 
(WHO) is establishing a global vaccine reserve for use in a potential deliberate release 
of smallpox. There have also been recent proposals for the WHO to allow the study of 
smallpox genes in other vectors. Together these facts are indications that the potential 
use of smallpox as a weapon ofbioterrorism cannot be ignored. 
As a result of the enduring threat of smallpox, the study ofpoxviruses is 
essential. The safety of researchers and difficulties associated with in vivo models of 
smallpox necessitate the use of related pox viruses in research efforts. During the WHO 
global eradication campaign vaccinia virus (VV) was utilized to vaccinate against 
smallpox. The efficacy of this program established the legitimacy of using other 
poxviruses to combat smallpox. 
Smallpox is not the only poxvirus that could be used as a bioterrorist agent. 
Other poxviruses infect humans with varying virulence. Genetically altering these 
pox viruses, moreover, could also lead to devastating effects. Understanding viral 
pathogenesis and finding antiviral agents against poxviruses are essential to modem 
day public health. 
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Aside from aiding in research to reduce the threat of these viruses, the study of 
pox viruses has its own merit. Poxviruses have a number of features that make them 
excellent vectors to deliver genes to cells. As vectors they can be used to study the 
effects of particular proteins or be utilized as recombinant vaccines. The 
characteristics that make poxviruses valuable vectors include administration through 
multiple routes, a large genome that can accommodate sizable fragments of foreign 
DNA, a broad host range, cytoplasmic replication, and ease of attenuation of the 
viruses (Vanderplasschen and Pastore!, 2003). To date, the safety and efficacy of 
poxviruses as vectors have been tested in both animal and human trials 
(Vanderplasschen and Pastore!, 2003). A recombinant VV (rVV)-rabies vaccine 
effectively decreased rabies incidents in wild foxes (Pastore! and Brochier, 1996). Not 
only can poxviruses be used as vaccines for other infectious agents, but they may be 
useful in cancer therapy. As vectors, poxviruses can express tumor-associated antigens 
or immune factors such as co-stimulatory molecules or cytokines to stimulate the 
immune system to attack and eliminate tumors; clinical studies with rVV expressing 
these factors have shown some efficacy in eliciting appropriate anti-tumor responses 
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(K wak et al., 2003). Thus, poxviruses as vectors are useful tools that will continue to 
develop and aid mankind. 
Moreover, the presence ofimmunomodulators in poxvirus genomes has also 
proven advantageous to science. These factors enable the virus to avert the immune 
system allowing optimum viral proliferation even in hosts with competent immune 
systems. Immunomodulators affect many aspects of the immune system including 
cytokine networks, complement activation, antigen presentation, and apoptosis (See! et 
al., 2003). The presence of these factors affect the virulence and pathogenesis of the 
viruses, as seen by the effects of deletion of these factors from the genome (Smith et 
al., 1999). Although of mainly deleterious effects to the host, these immunomodulators 
have provided some benefits to mankind. They have helped researchers gain a better 
understanding of the different components of the immune system and how they 
function. The role of interleukin (IL)-1 p, for example, was refined through study of a 
poxvirus immunomodulator (Smith et al., 1999). Additionally, some of these 
immunomodulators could potentially be used as therapeutic agents for other diseases. 
The therapeutic use ofVV complement control protein has been tested in different 
pathologies. Administration of this factor decreased spatial memory impairments after 
traumatic brain injury in rats (Hicks et al., 2002), decreased early bacterial counts after 
experimentally induced surgical peritonitis (Scott et al., 2003), and may be useful in 
xenografts by inhibiting the destruction of pig aortic endothelial cells by human 
complement and cytotoxic cells (Al-Mohanna eta!., 2001). Consequently, the study of 
these poxvirus immunomodulators is a valuable field of research. 
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Finally, the study of pox viruses will aid the creation of safer vaccines. 
Although general vaccination with VV has ceased since the eradication of smallpox, it 
is still given to military and laboratory personnel who may be exposed to poxviruses. 
Unfortunately, vaccination with VV is not completely safe. There are a number of 
adverse events associated with VV vaccination, including some that are potentially 
fatal (Bray, 2003; Fulginiti eta!., 2003). Attenuation of the virus can be achieved 
through the deletion of some immunomodulator genes, or potentially, by the insertion 
of beneficial cytokine genes in the viral genome. However, it is important that such 
vaccines are safe and yet still capable of stimulating a protective immune response. 
Further study with poxviruses is thus necessary to develop these vaccines. 
Pox viruses are classified in the family Poxviridae. Smallpox, or variola virus, 
is from the subfamily Chordopoxvirinae and genus Orthopoxvirus with related viruses 
including VV, cowpox virus (CPV), monkeypox virus, and ectromelia virus (EV) 
(Moss, 2001). The orthopoxviruses are enveloped viruses with a linear double-
stranded DNA genome; these viruses replicate in the cytoplasm and encode viral 
proteins necessary for transcription and replication (Moss, 2001). Poxvirus infection 
rapidly inhibits host DNA, RNA, and protein synthesis (Buller and Palumbo, 1991). 
The poxviruses in this study, CPV and VV, are capable of infecting a wide array of 
hosts (Fenner eta!., 1989). The reservoir hosts of CPV are rodents (Chantrey et a!., 
1999). Outbreaks ofCPV occur in people through contact with infected rodents, or 
with animals that come in contact with these rodents (Wolfs eta!., 2002; Coras eta!., 
2005). The original host ofVV is unknown, though some hypotheses exist as to its 
origins. It is speculated that either VV evolved from CPV or variola, a combination of 
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CPV and variola evolving together, or that the natural host no longer exists (Buller and 
Palumbo, 1991). 
In order to understand the pathogenesis of poxviruses it is requisite that 
researchers utilize in vivo models of infection. There are a number of different models 
of infection for poxviruses including: tail scarification, footpad infection, intracerebral, 
intranasal (i.n.), intradermal (i.d.), and intraperitoneal (i .p.) routes (Smith and Kotwal, 
2002; Smee and Sidwell, 2003). There are differences in outcomes of the virus 
infection based on which model is used. For example, infection with VV in the i.n. 
model results in a severe, systemic infection while in the i.d. model it causes a local 
infection (Tscharke and Smith, 1999; Tscharke et a!., 2002). The route of infection 
also influences the immune response. After i.d. infection with VV, neutrophils and 
a!~-T cells were strongly recruited whereas with i.n. infection the cellular response was 
mainly composed of macrophages and a/~-T cells (Reading and Smith, 2003a). A 
suitable model can be chosen depending on the purposes of a study. The i.d. model 
would be valuable in studying poxvirus vaccines, while an i.n. model would be useful 
to mimic the natural route of infection to analyze the efficacy of antiviral compounds. 
The breed of mice used must also be taken into consideration. Some inbred strains of 
mice are resistant to certain viruses while other strains are susceptible. This is 
demonstrated by the fact that C57BL/6 mice are naturally resistant to EV while 
BALB/c mice are susceptible (Buller and Palumbo, 1991). These inbred strains of 
mice also differ in their predisposition to which type ofT-helper (Th) cell responses 
they generate. Immunologically naive C57BL/6J mice are predisposed to a Th1 
response while BALB/cJ mice are predisposed to a Th2 response (Charles et a!., 1999). 
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The strain of the virus may also influence the outcome of infection. In the i.d. model, 
certain strains of VV produced large lesions while others were almost ineffective at 
causing lesion formation (Tscharke et al., 2002). These are some of the many factors 
that can influence an in vivo model. 
At this time, the best animal models for studying smallpox are monkeypox and 
variola infections in nonhuman primates. These models are the best representations of 
smallpox infections in humans. Monkeypox models using intravenous (Hooper et al., 
2004) and respiratory (Stittelaar et al., 2005) infections have been successfully used to 
demonstrate the efficacy of potential smallpox vaccines. The use of smallpox to infect 
monkeys is also being developed. In this model, high doses of variola virus are 
administered intravenously resulting in an infection that resembles a severe form of 
human smallpox infection (Jahrling et al., 2004). Although the course of the disease in 
this model skips over the initial stages of infection seen in humans, it enables the 
researchers to study the pathogenesis of smallpox and test antiviral compounds and 
vaccines against severe smallpox infections (Jahrling et al., 2004). Unfortunately these 
animal models cannot be widely utilized. Due to the rarity and the cost associated with 
monkeys, these models are only used by certain laboratories. Additionally, biosecurity 
restraints require that research with variola be confined to the Centers for Disease 
Control and Prevention in Atlanta, GA. Other laboratories are limited to other 
orthopoxvirus animal models. 
Although legitimately employed, it must also be remembered that murine 
models are not perfect representations of the human system. There are important 
differences in the immune systems of mice and humans. Some of these dissimilarities 
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include differing chemokine components (e.g., monocyte chemoattractant protein 
(MCP)-5 is present in mice but not humans), differences in Th responses (e.g., IL-10 is 
a Th2 cytokine in mice but both Thl and Th2 produce it in humans), or the role that 
immune factors play (e.g., interferon (IFN)-u stimulates Thl development in humans 
but not mice) (Mestas and Hughes, 2004). The importance of these differences in 
application is illustrated by the problems encountered in model studies. As an 
example, during a study of the virulence of the VV IFN-y receptor, the results were 
initially misleading due to the fact that the receptor did not have as high an affinity for 
murine IFN-y as for IFN-y from other species including humans (Symons et al., 2002). 
When utilizing animal models these difference must be kept in mind. 
Understanding the immune system and how it works is necessary when 
studying viruses. The immune response can be divided into two components: innate 
and adaptive. Innate immunity is responsible for the initial defense against pathogens. 
The components of innate immunity allow it to nonspecifically eliminate pathogens. 
Certain cytok:ines, complement, and natural killer (NK) cells can all be considered part 
of the innate immunity. The adaptive immune response specifically targets pathogens. 
This response is mediated by antibodies, cytotoxic T-lymphocytes (CTLs), and other 
lymphocytes. The division of the immune response into these two categories is not 
entirely distinct. Some components may have a role in both the adaptive and innate 
responses. Control of viral infections is dependent on both the innate and adaptive 
immune responses. NK and CTL cells both lyse virus-infected cells and produce 
antiviral cytokines such as IFN-y and tumor necrosis factor (TNF)-u which can 
eliminate viruses from infected cells without cell lysis (Guidotti and Chisari, 2001). 
Macrophages also play a role in the antiviral response via cytokine production and 
nitric oxide (NO) synthesis (Guidotti and Chisari, 2001). 
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Toll-like receptors (TLRs) on cells of the innate immune system are an 
essential component of the antiviral immune response and aid in the induction of 
cytokine responses. These receptors recognize pathogen-associated molecular patterns 
which activate a cellular signaling cascade leading ultimately to the release cytokines 
and induction of an appropriate immune response. There are I I known human TLRs 
(Boehme and Compton, 2004). TLRs are expressed on cells of the innate immune 
system, such as macrophages and dendritic cells, and also on epithelial and endothelial 
cells (Takeda et a!., 2003). These cells are also thus capable of responding to infection. 
TLRs also influence the development of the adaptive response as they affect the 
development ofThlffh2 response: TLR4 activation results in a Thl response while 
TLR2 induces a Th2 response (Netea et al., 2004). Research has shown that these 
receptors are involved in the antiviral response: TLR2 and TLR4 recognize viral 
envelope glycoproteins, TLR7 and TLR8 respond to single-stranded RNA, 
deoxycytidylate phosphate deoxyguanylate (CpG) DNA motifs activate TLR9, and 
TLR3 is stimulated by double-stranded RNA in various viral infections (Boehme and 
Compton, 2004). As an example ofthe importance of stimulation ofTLRs, 
administration ofCpG DNA served to protect mice from VV i.n. infections and 
reduced titers 10,000-fold in the lungs (Rees et al., 2005). Moreover, VV protein 
A52R blocks signaling molecules and is thus an inhibitor of multiple TLRs, 
particularly TLR3 (Harte et al., 2003). 
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Interferons are well known for their antiviral properties. They are divided into 
two classes: type I and type II. IFN-a and IFN-P are type I interferons while IFN-y is 
the only type II interferon. Both types of interferon induce the antiviral state through 
the enzymes oligoadenylate synthetase and protein kinase PKR, which are involved in 
the degradation of viral RNA and inhibition of viral translation respectively (De 
Maeyer and De Maeyer-Guignard, 1998). Interferons also aid in viral resolution by 
increasing NK cytolysis (Biron et al., 1999). The importance of interferons in antiviral 
immune responses is illustrated by results obtained from mice in which interferons do 
not function. Mice lacking the type I interferon receptors were increasingly susceptible 
to lymphocytic choriomeningitis virus, Semliki Forest virus, VV, and vesicular 
stomatitis virus (Miiller et al. , 1994). Interferons are vital antiviral cytokines in the 
immune responses. 
The major histocompatibility complexes (MHC) are proteins on cell surfaces 
that play a role in immunity. They bind and present antigens to immune cells to elicit 
appropriate responses. MHC class I receptors bind antigens degraded in the cytoplasm 
while MHC class II receptors bind antigens from intracellular vesicles. MHC class I 
receptors, which are found on almost all cell types, complex with CDS+ cells, while 
MHC class II receptors, which are found on immune effector cells, associate with 
CD4+ T cells. Both type I and II interferons can stimulate MHC class I antigen 
expression while IFN-y also enhances MHC class II antigen expression (Biron and Sen, 
2001). Increased MHC class I expression subsequently increased lysis of virus-
infected cells by CTLs (De Maeyer and De Maeyer-Guignard, 1998). 
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T -helper (Th) cells are also important in controlling viral infections. There are 
two main subsets ofTh cells, Th1 and Th2, which are associated with the induction of 
the cellular and humoral responses respectively. The Th subsets produce distinct 
patterns of cytokines. Murine Th1 cells produce IL-2, IFN-y, and lymphotoxin while 
murine Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13; human Th subsets 
produce similar patterns as mouse subsets though some cytokines are not as strictly 
relegated to a specific subset (Mosmann and Sad, 1996). The polarization of the 
appropriate Th response depends on both cytokines and chemokines. IL-12, IFN-y, 
and transforming growth factor-~ stimulate Thl polarization and IFN-y inhibits Th2 
induction; on the other hand, IL-4 causes Th2 differentiation and IL-l 0 inhibits Th 1 
responses (Mosmann and Sad, 1996). Chemokines also influence Th response. It has 
been shown that the chemokines macrophage inflammatory protein (MIP)-1 a, MIP-1 ~. 
and RANTES affect murine Thl cells but not Th2 cells (Siveke and Hamann, 1998). 
The expression of chemokine receptors on the two subsets also indicates the effect that 
chemokines have on specific Th responses. In humans, Th1 cells express CXCR3 and 
CCR5 on their cell surfaces while Th2 cells express CCR3 and CCR4 (Bonecchi et al., 
1998; Sallusto et al. , 1998). Thl and Th2 polarization has been shown to be important 
in the antiviral immune response. Resistance or susceptibility to EV is correlated with 
Thl or Th2 responses respectively. C57BU6J mice, which are resistant to EV, 
strongly induce Th1 cytokines IL-2, TNF, and IFN-y compared to susceptible BALB/c 
mice in response to EV infections (Chaudhri et al., 2004). Infection with rVV 
expressing IL-4, a Th2 cytokine, delayed viral clearance as well as reduced CTL 
precursor cells, CTL lysis, and expression ofTh1 cytokines IL-12, IL-2, and IFN-y 
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mRNA (Sharma et al., 1996). Furthermore, infection with VV strain Western Reserve 
(WR) in C57BU6 mice lacking IL-12, which stimulate a Thl response, resulted in 
higher virus titers than controls while on the other hand infection in IL-l o-l-mice and 
IL-4_1_ mice showed reduced virus titers (van den Broek et al., 2000). These findings 
indicate that Th2 responses hinder recovery from poxvirus infections. 
Although it is generally accepted that recovery from viral infections requires 
the CTL lytic response, evidence indicates that the necessity of this response depends 
on the virus. CTLs release perforin and other enzymes to lyse infected cells. Thus the 
findings that perforin deficient effector cells, but not IFN-y deficient effector cells, 
were able to reduce virus titers ofVV while the reverse was true for EV indicate that 
VV infections can be overcome in a cytolytic deficient environment while EV 
infections seem to need a cytolytic response for recovery of the host (Ramshaw et al., 
1997). Research with VV seems to indicate that the CTL cytolytic response is not as 
crucial as other factors for recovery from disease. This is clearly demonstrated by the 
results showing that mice without the IFN-y receptor were able to mount normal CTL 
cytolysis, but were at an increased susceptibility to VV as measured by increased viral 
replication and mortality (Huang et al., 1993). C57BU6 MHC class I, CD8+ T cell 
deficient mice are capable of overcoming i.d. VV WR infections like normal mice 
(Spriggs et al., 1992). Additionally, C57BU6 CD4+ depleted mice (which maintained 
CTL cytotoxicity to VV) infected with VV WR i.p. showed I 00-fold more titer while 
CD8+ depleted mice had similar titers as controls (Xu et al., 2004). Correspondingly, 
these investigators also demonstrated that MHC class n-l-mice hr-td higher titers than 
CD8-I- mice which responded like the normal animals did to infection (Xu et al., 2004). 
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Although some may argue that the studies of Sharma eta!. (1996) and van den Broek et 
a!. (2000) using rVV expressing IL-4 and IL-12 deficient mice respectively, indicate 
that CTL lysis is crucial to the resolution of VV infections, their findings are probably 
the result of the lack of important CTL or Thl cytokines and other Thl effects not 
merely the reduction of CTL cytolysis. For example, rVV expressing IL-4 also 
suppressed NO production, which is important in inhibiting VV infections (Sharma et 
a!., 1996). The CTL response in poxvirus infections is not to be completely 
disregarded. MHC class rr'- CDS+ depleted mice showed increased morbidity 
compared to mere MHC class rr'· mice to VV infection (Xu et a!. , 2004). There is 
clearly a role for the CTL response in VV viral clearance; however, it cannot be 
construed as the most important immune response, at least in VV infections. 
Cytokines are components of the immune system that have many functions. 
These proteins are involved in regulating immune effector cells, chemotaxis of 
leukocytes, Th polarization, development of the antiviral state, and regulation of 
antibody production. Correspondingly, cytokine profiles have been associated with 
certain aspects of illness. Rock et a!. (2004) showed that systemic IFN-y levels were 
elevated in response to the A ventis Pasteur smallpox vaccine and that certain vaccine 
related adverse events were associated with an increase ofiFN-y, IL-10, IL-5, IL-2, IL-
4, and TNF-u concentrations in particular patterns. Modulation of cytokines 
demonstrates their integral role in the immune response. For example, infection of a 
rVV encoding IL-2 enhanced survival of immunodeficient mice and reduced morbidity 
(Flexner eta!., 1987; Ramshaw eta!., 1987). Modulation ofcytokines can also 
increase disease severity. C57BU6 mice which are normally resistant to EV are 
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rendered susceptible when deficient in IFN-y and IFN-a/~ or when infected with a 
recombinant ectromelia virus (rEV) expressing IL-4 (Ramshaw et al., 1997; Jackson et 
al., 2001 ). Intriguingly, previously EV immunized mice were also at increased 
susceptibility to rEV expressing IL-4 (Jackson et al., 2001). Furthermore, cytokines 
can be administered to assist the host in overcoming viral infections. Liu et al. (2004) 
demonstrated that IFN-u and IFN-y successfully reduced virus titers 1,000- to I 0,000-
fold and decreased mortality in an VV i.n. infection. The fact that some viral 
immunomodulators target cytokine function also illustrates their important role in viral 
infections. Interestingly enough, viruses are not the only pathogens that modulate 
cytokine function. The saliva of certain species of ticks have been shown to inhibit 
activity of a number of cytokines (Hajnicka et al., 2005). 
Many studies indicate that cytokines may be the most critical factor in 
resolution of viral infections. Citing rapid viral clearance in transgenic hepatitis B 
virus mice following transfer of CTLs incapable of cytolysis and also pointing out that 
cytolysis could not eliminate all infected cells in large organs due to sheer numbers and 
functional recovery of these organs after viral clearance, Guidotti and Chi sari (200 I) 
make the case that CTL antiviral cytokines are just as efficient if not more important in 
viral immune responses than the CTL lytic processes. As well as these arguments, 
rVV expression ofiFN-y or TNF-u reduced virus pathogenicity and increased viral 
elimination in vivo in the absence ofT cells (Ramshaw et al., 1997). 
Chemokines are chemoatti-actant cytokines. They are classified based on the 
presence of cysteine residues and intervening amino acids. Thus CXC chemokines 
have two cysteines interrupted by another amino acid while CC chemokines have two 
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adjacent cysteine residues. In general, CC chemokines are chemotactic for monocytes, 
lymphocytes, basophils, eosinophils, dendritic cells, and NK cells while CXC 
chemokines attract and activate neutrophils (Wuyts et al., 1998). Chemokines aid both 
the innate and adaptive immune response during viral infections. Certain chemokines 
including MIP-lu and IFN-y inducible protein (IP)-10 have been found to increase NK 
cell migration and cytolysis (Taub et al., 1995). Chemokines can also influence the 
adaptive immune system by polarizing the Th response, attracting appropriate immune 
effector cells, and increasing cytotoxicity of CTLs and NK cells (Lusso, 2000; 
Mahalingam et al., 2003). The presence of viral immunomodulators that target 
chemokines also underscores their importance in antiviral immune response. However, 
chemokine responses can be a two-edged sword assisting in the resolution of viral 
infections but potentially contributing to disease pathology. In some viral infections 
virus elimination of specific chemokines reduced tissue damage and disease severity 
(Mahalingam et al., 2003). Not only are chemokines important mediators ofleukocyte 
migration but also the antiviral response. 
This study characterizes the cytokine elements of two murine models used to 
analyze anti-orthopoxvirus compounds: the i.n. and i.p. models. The i.n. model results 
in high virus titers particularly in the lungs and snout and has high mortality (Smee et 
al., 2001a; Smee et al. , 2001b); it is thus a suitable model for studying the effects of 
potential antiviral compounds. Additionally, the i.n. model mimics the route of 
exposure to pathogens should a bioterrorist attack occur. Infection via the i.p. route has 
a markedly different pathogenesis than the i.n. model, with the mortality affected by 
dose (Smee and Sidwell, 2003). A high dose given i.p. also initiates a severe infection 
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which makes it a useful model in studying the effects of antiviral compounds on severe 
systemic infections. In this study, the cytokine profiles and time-course of induction 
were characterized for CPV and VV infections in both of these models. The effects of 
cidofovir, an antiviral compound, on these factors were also analyzed. 
An examination of the effects ofVV and CPV on the sys1.emic cytokine profile 
in these models has not been established. One study reported that IFN-y, TNF-a and 
certain chemokines in the bronchoalveolar lavage (BAL) fluid of mice infected i.n. 
with 104 plaque forming units (p.f.u.) VV WR were present only at low levels on days 
I and 3 post-infection (p.i .), peaked at days 7 and 10, then decreased by day 15 after 
infection (Reading and Smith, 2003a). Rocket al. (2004) documented systemic 
cytokine profiles in human vaccinees. However, vaccination does not represent a 
severe infection and does not usually require antiviral compounds to control. Other 
studies have analyzed the effects of specific factors on certain cytokine levels in lungs 
and serum (Reading and Smith, 2003b; Rees et al. , 2005). Analyzing the cytokines in 
the proposed models is thus justifiable. 
The use of antiviral compounds on orthopoxviruses has been widely studied 
(Smee and Sidwell, 2003). (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine 
(cidofovir or HPMPC), a cytosine derivative, is one of the most useful antiviral agents 
for orthopoxviruses. It successfully aided in survival of mice infected with lethal doses 
of CPV strain Brighton (BR) by the i.n. or aerosol routes (Bray et al., 2000). Cidofovir 
treatment also reduced viral titers and increased survival of mice infected i.n. with VV 
WR (Smee et al., 2001a; Smee et al., 200lb). However, cidofovir treated mice still 
showed some signs of morbidity as they developed similar weight loss as placebo mice 
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in both CPV and VV i.n. infections (Bray et al., 2000; Smee et al., 200la; Smee et al., 
200 I b). A subcutaneous dose of30 or I 00 mg/kg cidofovir given on days I and 4 after 
virus exposure increased survival and decreased other infection parameters in VV i.n. 
infected animals (Smee et al., 200la). Treatment with a single 100 mg!kg cidofovir 
dose i.p. given 24 hours after virus exposure also significantly reduced mortality and 
virus titers in VV i.n. infected mice (Smee et al., 200lb). Cidofovir protected 80-100 
percent ofCPV i.n. infected animals when a single subcutaneous dose of 100 mg!kg 
was administered 6 days prior to or 2 days after infection (Bray et al., 2000). Cidofovir 
also maintains antiviral effect for i.n. CPV BR and VV WR challenges when a single 
i.p. dose of 30 or I 00 mg/kg cidofovir was given as late as day 3 p.i. (Quenelle et al., 
2003). Although cidofovir did not prevent mortality in i.p. CPV BR or VV WR 
infections in severe combined immunodeficient mice, treatments did delay the mean 
day of death and reduced or delayed virus titers (Quenelle et al. , 2003). When severe 
combined immunodeficient mice infected with CPV i.n. were treated with cidofovir 
they also had a delayed time to death (Bray et al., 2000). As perhaps the most effective 
anti-orthopoxvirus compounds cidofovir was chosen to determine the effects of 
antiviral treatment on cytokine levels during orthopoxvirus infections in mice. 
17 
MATERIALS AND METHODS 
Antiviral Compound 
Cidofovir was obtained from Mick Hitchcock of Gilead Sciences (Foster City, 
CA). Cidofovir doses were prepared in sterile saline. Sterile saline served as the 
placebo control. 
Viruses and Cells 
VV strain WR was purchased from the American Type Culture Collection 
(ATCC) (Manassas, VA). CPV strain BR was obtained from John Huggins at the US 
Army Medical Research Institute of Infectious Diseases (Ft. Detrick, Frederick, MD). 
Joseph Esposito of the Centers for Disease Control and Prevention (Atlanta, GA) 
originally provided this virus to Dr. Huggins. High titer virus pools were prepared in 
African green monkey kidney (MA-l 04) cells purchased from Bio Whittaker 
(Walkersville, MD). The CPV virus was passed through African green monkey kidney 
(Vero 76) cells from ATCC and a high titer pool of a syncytium-forming plaque 
purified isolate was obtained (Smee eta!., 2002). For VV, the virus was then passed 
once through immunosuppressed hairless mice and a high titer pool obtained from skin 
lesions (Smee eta!., 2004). Another line of African green monkey kidney (Vero) cells 
purchased from ATCC were used for plaque assays. These cells were cultured in 
Eagle' s medium (MEM) containing 5% fetal bovine serum. For plaque assays, MEM 
containing 2% fetal bovine serum was used. 
Mouse Infections and Serum Collection 
Four murine models of poxvirus infection were studied. These models were 
CPV i.n. , CPV i.p., VV i.n. , and VV i.p. infections. 
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13-15g female BALB/c mice were obtained from Charles River Laboratories 
(Wilmington, MA). They were quarantined for at least 24 h prior to experiment 
initiation. Mice were infected with 3x105 p.f.u./mouse i.n. or 3-5x106 p.f.u./mouse i.p. 
with CPV BR or VV WR. Virus stocks were sonicated 20-30 s before dilution in 
MEM media. Virus doses were given in 50 J.ll volume i.n or 0.1 ml volume i.p. During 
i.n. infections mice were anaesthetized using ketamine (l 00 mglkg i.p.) diluted in 
sterile saline. For antiviral studies, mice were treated i.p. with 100 mglkg cidofovir in 
0.1 ml volumes once a day on days 1 and 2 after virus exposure. Previous work has 
demonstrated that a dose of 100 mglkg of cidofovir protects mice against poxvirus 
infections (Bray et al., 2000; Smee et al., 2001 b). Efficacy of the drug increases when 
given in multiple doses (Smee et al., 2001a). Observations indicate that treatments of 
100 mglkg cidofovir on days 1 and 2 after virus exposure are highly effective. 
Serum was collected by anaesthetizing the animals using Avertin diluted to 5% 
in sterile water and given 0.15 ml i.p. After the mice had succumbed to the anesthesia, 
the brachial artery was severed and in some cases the heart in addition to the brachial 
artery. Blood was collected from the site of incision. The blood was allowed to clot 
and then centrifuged at approximately 4800 xg for 7 min. The serum was stored at 
-80°C until use. 
There were a few mice in the i.p. models that were considered "non-
responders" indicating a mild infection. These mice appeared healthy in stark contrast 
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to their cohorts. As observations showed that non-responders had low virus titers 
compared to other mice within the same groups they were not included in the data for 
this study. 
Cytokine Profiles 
Groups of at least 6 mice were infected with the viruses for the four models 
studied. Pooled serum was used to obtain the cytokine profiles in the following 
manner. The i.n. models were analyzed initially using Panomics TranSignal Mouse 
Cytokine Antibody Array 1.0 (Redwood City, CA). For this assay, serum was 
collected on day 6 p .i. for CPV infections and day 5 p.i. for VV. These mice received 
placebo treatment. Later in the study, pooled serum samples were shipped to Charles 
River Laboratories (Wilmington, MA) for analysis via Rules-Based Medicine mouse 
Multi-Analyte Profile (MAP) testing. For the MAP analyses, the serum samples were 
collected on day 6 for the i.n. models, which also received placebo treatment, and day 4 
for the i.p. models, which did not have any treatment. Days of serum collection 
differed in the i.n. and i.p . models based upon time to death. 
Time-course ofCytokine Induction and 
Effects of Antiviral Treatment on 
Cytokine Concentrations 
The cytokine concentrations for the time-course and antiviral treatment studies 
were determined using commercially available ELISA kits. IL-6 and MCP-I 
concentrations were quantified using ELISA kits from Pierce Endogen (Rockford, IL). 
The BD Biosciences mouse IFN-y kit (San Diego, CA) and R&D Systems mouse IP- I 0 
ELISA kit (Minneapolis, MN) were used for the detection of IFN-y and IP- I 0, 
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respectively. The sensitivities of the assays were <7 pg/ml for IL-6, <4 pg/ml for 
MCP-1 , 14 pg/ml for IFN-y, and 2.2 pg/ml for IP-10. All samples were assayed in 
duplicate. If undiluted samples were below the standard curve the values were reported 
as the appropriate sensitivity. 
A time-course of cytokine induction was determined for all four models of 
infection. Serum was collected from mice on days I , 3, and 5 p.i . for all models except 
for the CPV i.n. model, during which serum was collected on days 1, 3, 5, and 7 p.i . 
This schedule of collection was based upon time to death for each model. 
Concentrations ofiFN-y, IL-6, IP-10, and MCP-1 were also measured during an 
antiviral study. For each model of infection one group of mice received cidofovir 
treatments while the other group received placebo. Serum collection occurred on day 5 
p.i. for all models except for the CPV i.n. model in which serum was collected on day 7 
p.i. Pooled serum from each group was also sent to Charles River Laboratories for 
MAP testing. 
Survival, Mean Body Weight, and Virus 
Titer Determinations 
Groups of 10 to 12 mice were infected and given antiviral treatment. During a 
period of 21 days the mean body weight per group was obtained every 2 to 3 days and 
the mortality was observed. In a parallel study, groups of mice from all four models 
were treated with cidofovir or placebo. The mice were sacrificed on day 6 p.i. at which 
time the brains, spleens, livers, lungs, and snouts were collected. If the mice died prior 
to the day of sacrifice, tissues were collected post mortem to obtain enough samples for 
analysis. Tissues were homogenized in MEM or Dulbeco's modified Eagle's media 
21 
(DMEM/high glucose) and stored at -80°C. Virus titers were determined by plaque 
assay. Samples were centrifuged to obtain the supernatant which was serially diluted 
with MEM or DMEM/high glucose media then titrated in confluent Vero cell 
mono layers in 12-well plates. The plates were rocked every 5 min for 45 min after 
addition of the dilutions to ensure a high degree of virus adsorption. After this time, 
MEM with 2% fetal bovine serum was added to each well. The cells were incubated 
for 72 hours. Following incubation the plaques were visualized with crystal violet 
stain and counted. Data were converted to plaque forming units (p.f.u.) per gram of 
tissue. 
Statistical Methods 
Statistical analyses were made between cidofovir and placebo treated groups. 
Cytokine levels were compared using the t-test with Welch correction. Virus titers and 
mean day of death were analyzed using the Mann-Whitney U-test. The Fisher's exact 
test was used to determine differences in survivor ratios. All P-Yalues reported are 
two-tailed analyses. Calculations were performed using GraphPad InStal version 3.0 
for Macintosh, GraphPad Software (San Diego, CA). In this report the term 





The results from the Panomics assays indicate differences in cytokine induction 
for the CPV i.n. and VV i.n. models (Figure 1). These results were tabulated based on 
the comparative strength of the signal for each assay (Table 1 ). The data indicate 
strong granulocyte-colony stimulating factor (G-CSF), IL-6, and IL-l 0 responses with 
slight induction ofRANTES during CPV i.n. infections. VV i.n. infection stimulated 
marked induction ofG-CSF with slight monokine induced by IFN-y (MIG), IFN-y, IL-
6, IP-10, and RANTES responses. 
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Fig. I. Cytokine induction in CPV i.n. (A), VV i.n. (B), and uninfected mice (C). 
Pooled serum was collected from infected mice on day 6 after virus exposure for CPV 
i.n. infected mice and day 5 after virus exposure for VV i.n. infected mice. These mice 
received placebo treatment i.p. once a day for two days starting 24 h after virus 
exposure. Cytokine induction determined by Panomics assays. Serum was diluted 3-
fold to perform the assays. Signals were detected using a Kodak Image Station 2000R. 
Each cytokine is spotted in duplicate on the membranes. 1, granulocyte-colony 
stimulating factor; 2, monokine induced by interferon-y; 3, interferon-y; 4, tumor 
necrosis factor-a; 5, interferon-y inducible protein-10; 6, RANTES; 7, interleukin (IL)-
6; 8, IL-l 0. The far right columns are the positive controls. 
Table I 
Tabulated cytokine induction in CPV i.n., VV i.n., and uninfected mice• 
Cytokine6 CPV i.n. VV i.n. Uninfected 



























• Pooled serum was collected on day 6 after virus exposure for CPV and day 5 after 
virus exposure for VV infected mice. Mice received placebo treatment i.p. once a day 
for two days after virus exposure. Cytok:ine induction determined by Panomics assays. 
b G-CSF, granulocyte-colony stimulating factor; M-CSF, macrophage-colony 
stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; MIG, 
monokine induced by interferon-y; MIP, macrophage inflammatory protein; IFN, 
interferon; TNF, tumor necrosis factor; IP, interferon-y inducible protein; RANTES, 
regulated upon activation, normally T-cell expressed and secreted; VEGF, vascular 
endothelial cell growth factor; IL, interleukin. 
+ strength of signal. 
Cytokine profiles as determined by MAP testing were more extensive than the 
Panomics assays {Tables 2-5). The i.n . mice were assayed at a different time than the 
i.p. mice but pooled serum from uninfected animals was sent with each group as a 
control. Fold changes were calculated from the average of both uninfected samples. If 
the sample had a value not determinable on the standard curve the least detectable dose 
was substituted to calculate the fold change. Some new assays were introduced 
Table 2 
AnalY!e profile in CPV i.n. infected mice' determined from MAP anal~sis ofEooled serum 
Anal~t;o Units LDD Cone. A Uninfeeted• Anal~te Units LDD Cone. A Uninfected 
ApoAI J.lg/ml 10 165 1.0 160 Insulin ).liU/ml 2.0 LOW 0.4 4.6 
CRP J.lg/mL 0.53 1.0 1.7 0.5965 IP-10 pglml 40 846 5.4 155.6 
EGF pglml 39 30 2.9 10.385 KC/GROa nglml 0.17 LOW 1.0 LOW 
Endothelin-1 pglml 67 6.5 0.2 37.615 Leptin nglml 0.096 0.47 0.5 0.8535 
Eo tax in pglml 12 1,830 4.8 379.5 LIF pglml 44 164 1.9 86.35 
Factor VII nglml 0.96 0.64 1.0 0.63 Lymphotactin pglml 85 464 2.9 161.5 
FGF-9 nglml 0.99 1.6 1.6 LOW MCP-1 pglml 17 8,620 54.2 !59 
FGF-basic nglml 0.58 0.42 0.6 0.6705 MCP-3 pglml 31 3,040 12.3 246.5 
Fibrinogen uglml 12 235 2.2 108 MCP-5 pglml 46 8,255 56.9 145 
GCP-2 nglml 0.025 9.1 1.2 7.59 M-CSF nglml O.ot8 4.3 0.8 5.305 
GM-CSF pglml 8.7 22 2.6 8.263 MDC pglml 22 473 1.1 440 
GH nglml 0.30 0.020 0.5 0.0445+ MIP-la nglml 0.23 0.077 0.4 0.176 
GST nglml 2.3 0.21 1.0 0.207+ MIP-1~ pglml 78 991 12.8 LOW 
Haptoglobin ).lg/ml 0.64 99 2.9 33.85 MIP-ly nglml 0.074 58 5.4 10.8 
IFN-y pglml 68 290 4.3 LOW MIP-2 pglml 7.2 42 4.7 8.887 
lgA J.lg/ml 1.9 88 0.7 130 MIP-3~ nglml 0.47 0.24 1.3 0.1825 
IL-10 pglml 109 3,360 18.4 182.5 MMP-9 nglmL 10 51 1.0 49.95 
IL-11 pglml 87 1,180 13.5 LOW Myoglobin nglml 24 846 6.4 133 
IL-12p70 nglml 0.57 0.68 1.2 LOW OSM nglml 0.13 0.52 4.0 LOW 
IL-17 nglml 0.15 0.28 1.8 LOW RANTES pglml 48 171 3.6 LOW 
Table 2 (continued) 
Anal)'teb Units LDD Cone. A Uninfeeted' Anal)lte Units LDD Cone. A Uninfeeted 
IL-18 ng/ml 0.67 0.61 0.6 0.9935 SCF pg/ml 75 479 8.8 54.21 
IL-Ia pg/ml 45 382 1.2 328.5 SGOT f!g/ml 1.9 24 1.1 22.4 
!L-IP ng/ml 0.45 0.18 0.5 0.337 TIMP-1 ng/ml 0.18 52 31.7 1.625 
IL-2 pg/ml 67 124 1.9 LOW Tissue Factor ng/ml 0.52 3.5 1.0 3.49 
IL-3 pg/ml 21 18 0.8 LOW TNF-u ng/ml 0.14 0.27 2.0 LOW 
IL-4 pg/ml 74 77 1.0 LOW TPO ng/ml 2.7 10.0 0.9 II 
IL-5 ng/ml 0.19 0.043 0.4 0.1155 VCAM-1 ng/mL 0.95 1,010 0.6 1650 
IL-6 pg/ml 14 5,970 431.0 LOW VEGF pg/ml 38 454 3.4 135.5 
IL-7 ng,lml 0.31 0.17 0.5 LOW vWF ng,lml 99 59 1.1 53.9 
• Serum was collected on day 6 after virus exposure. These mice received placebo treatment i.p. once a day for two days starting 24 
h after virus exposure. 
Cone. concentration. 
LDD least detectable dose. 
A fold change compared to uninfected mice. 
LOW values not determinable on the standard curve. 
b Apo AI, Apolipoprotein AI; CRP, C reactive protein; EGF, epidermal growth factor; FGF, fibroblast growth factor; GCP, 
granulocyte chemotactic protein; GM-CSF, granulocyte macrophage-colony stimulating factor; GH, growth hormone; GST, 
glutathione S-transferase; IFN, interferon; lg, immunoglobulin; IL, interleukin; IP, interferon-y inducible protein; KC/GROu, 
melanoma growth stimulatory activity protein; LIF, le~;kemia inhibitory factor; MCP, monocyte chemoattracta::t protein; M-CSF, 
macrophage-colony stimulating factor; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; MMP, 
matrix metalloproteinase; OSM, oncostatin M; RANTES, regulated upon activation, nom1ally T-cell expressed and secreted; SCF, 
stem cell factor; SGOT, serum glutamic-oxaloacetic transaminase; TIMP, tissue inhibitor ofmetalloproteinase; TNF, tumor necrosis 
factor; TPO, thrombopoietin; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial cell growth factor; vWF, von 
Willebrand factor. 
' Average of two samples sent at separate times. 
+ Does not represent average of two samples due to new assays added between times of analysis of two samples. 
Table 3 
Anal;t!e profile in CPV i.J2. infected mice" determined from MAP anal;tsis of12ooled serum 
Anal;tte" Units LDD Cone. A Uninfeeted' Anal:tte Units LDD Cone. A Uninfeeted 
ApoAI 11g/ml 10 128 0.8 160 IL-7 ng/ml 0.31 LOW 1.0 LOW 
CD40 pg/mL 12 386 1.2 330+ Insulin 11IU/ml 2.0 2.7 0.6 4.6 
CD40 Ligand pg/mL 92 LOW 0.3 283+ IP-10 pg/ml 40 214 1.4 155.6 
CRP 11g/mL 0.53 0.45 0.8 0.5965 KC/GROu ng/ml 0.17 0.13 0.7 LOW 
EGF pg/ml 39 LOW 3.8 10.385 Leptin ng/ml 0.096 0.57 0.7 0.8535 
Endothelin-1 pg/ml 67 LOW 1.8 37.615 LIF pg/ml 44 66 0.8 86.35 
Eo tax in pg/ml 12 2,000 5.3 379.5 Lymphotactin pg/ml 85 172 1.1 161.5 
Factor VII ng/ml 0.96 0.34 0.5 0.63 MCP-1 pg/ml 17 6,230 39.2 159 
FGF-9 ng/ml 0.99 LOW 1.0 LOW MCP-3 pg/ml 31 3,040 12.3 246.5 
FGF-basic ng/ml 0.58 LOW 0.9 0.6705 MCP-5 pg/ml 46 3,210 22.1 145 
Fibrinogen ug/ml 12 149 1.4 108 M-CSF ng/ml 0.018 3.6 0.7 5.305 
GCP-2 ng/ml 0.025 6.9 0.9 7.59 MDC pg/ml 22 384 0.9 440 
GM-CSF pg/ml 8.7 1.8 0.2 8.263 MIP-Iu ng/ml 0.23 0.070 0.4 0.1 76 
GH ng/ml 4.2 73 4.6 15.9+ MIP-IP pg/ml 78 531 6.8 LOW 
GST-u ng/ml 0.42 LOW 1.0 LOW+ MIP-ly ng/ml 0.074 49 4.5 10.8 
Haptoglobin 11g/ml 0.64 140 4.1 33.85 MIP-2 pg/ml 7.2 18 2.0 8.887 
IFN-y pg/ml 68 38 0.6 LOW MIP-3P ng/ml 0.47 0.46 2.5 0.1825 
IgA 11g/ml 1.9 113 0.9 130 MMP-9 ng/mL 10 36 0.7 49.95 
IL-10 pg/ml 109 3,950 21.6 182.5 Myoglobin ng/ml 24 63 0.5 133 
IL-11 pg/ml 87 244 2.8 LOW OSM ng/ml 0.13 0.092 0.7 LOW 
Table 3 (continued) 
Anall:teb Units LDD Cone. 11 Uninfeeted• Anall:te Units LDD Cone. 
IL-12p70 ng/ml 0.57 0.23 0.4 LOW RANTES pg/ml 48 85 
IL-17 ng/ml 0.15 0.068 0.4 LOW SCF pg/ml 75 89 
IL-18 ng/ml 0.67 1.00 1.0 0.9935 SGOT 11g/ml 1.9 32 
IL-Ia pg/ml 45 396 1.2 328.5 TIMP-1 ng/ml 0.18 15 
IL-l~ nglml 0.45 0.23 0.7 0.337 Tissue Factor ng/ml 0.52 2.5 
IL-2 pg/ml 67 15 0.2 LOW TNF-a nglml 0.14 0.027 
IL-3 pg/ml 21 LOW 1.0 LOW TPO ng/ml 2.7 9.4 
IL-4 pg/ml 74 LOW 1.0 LOW VCAM-1 ng/mL 0.95 1,170 
IL-5 ng/ml 0.19 0.086 0.7 0.1155 VEGF pglml 38 177 
IL-6 ~&ml 14 1,440 104.0 LOW vWF n&ml 99 30 
• Serum was collected on day 4 after virus exposure. 
Cone. concentration. 
LDD least detectable dose. 
6 fold change compared to uninfected mice. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
c Average of two samples sent at separate times. 

























Anall!e profile in VV i.n. infected mice• determined from MAP anal}'sis of pooled serum 
Anall'te" Units LDD Cone. A Uninfeeted' Anall'te Units 
ApoA1 J.lg/ml 10 159 1.0 160 Insulin J.lilllml 
CRP J.lg/mL 0.53 0.50 0.8 0.5965 IP-10 pglml 
EGF pglml 39 16 1.6 10.385 KCIGROa nglml 
Endothelin-1 pglml 67 13 0.3 37.615 Leptin nglml 
Eotaxin pglml 12 1,080 2.8 379.5 LIF pglml 
Factor VII nglml 0.96 0.77 1.2 0.63 Lymphotactin pglml 
FGF-9 nglml 0.99 0.45 0.5 LOW MCP-1 pglml 
FGF-basic nglml 0.58 1.2 1.8 0.6705 MCP-3 pglml 
Fibrinogen uglml 12 114 1.1 108 MCP-5 pglml 
GCP-2 nglml 0.025 5.4 0.7 7.59 M-CSF nglml 
GM-CSF pglml 8.7 12 1.5 8.263 MDC pglml 
GH nglml 0.30 0.033 0.7 0.0445+ MIP-la nglml 
GST nglml 2.3 0.68 3.3 0.207+ MIP-Ip pglml 
Haptoglobin J.lg/ml 0.64 90 2.7 33.85 MIP-ly nglml 
IFN-y pglml 68 3,510 51.8 LOW MIP-2 pglml 
IgA J.lg/ml 1.9 83 0.6 130 MIP-3~ nglml 
IL-10 pglml 109 666 3.6 182.5 MMP-9 ng!mL 
IL-11 pglml 87 787 9.0 LOW Myoglobin nglml 






























































Table 4 (continued) 
Anal~teb Units LDD Cone. A Uninfeeted' Anal~te Units LDD Cone. A Uninfeeted 
IL-17 ng/ml 0.15 0.029 0.2 LOW RANTES pg/ml 48 93 1.9 LOW 
IL-18 ng/ml 0.67 2.9 2.9 0.9935 SCF pg/ml 75 165 3.0 54.21 
IL-lu pg/ml 45 377 1.1 328.5 SGOT f.Lg/ml 1.9 22 1.0 22.4 
IL-Ip ng/ml 0.45 0.29 0.9 0.337 TIMP-1 ng/ml 0.18 32 19.9 1.625 
IL-2 pg/ml 67 28 0.4 LOW Tissue Factor ng/ml 0.52 4.3 1.2 3.49 
IL-3 pg/ml 21 7.0 0.3 LOW TNF-u ng/ml 0.14 0.17 1.3 LOW 
IL-4 pg/ml 74 28 0.4 LOW TPO ng/ml 2.7 II 1.0 II 
IL-5 ng/ml 0.19 0.12 1.0 0.1155 VCAM-1 ng/mL 0.95 1,740 1.1 1650 
IL-6 pg/ml 14 423 30.5 LOW VEGF pg/ml 38 404 3.0 135.5 
IL-7 n~ml 0.31 0.088 0.3 LOW vWF n~ml 99 92 1.7 53.9 
• Serum was collected on day 6 after virus exposure. These mice received placebo treatment i.p. once a day for two days starting 24 h 
after virus exposure. 
Cone. concentration. 
LDD least detectable dose. 
A fold change compared to uninfected mice. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
'Average of two samples sent at separate times. 
+ Does not represent average of two samples dt:e to new assays added between times of analysis of two samples. 
Table 5 
Anali:!e profile in VV i.J2 . infected mice' determined from MAP anal}'sis ofJ200led serum 
Anal}'t;t> Units LDD Cone. a Uninfeeted' Anal}'te Units 
ApoAl Jlg/ml 10 171 1.1 160 IL-7 ng/ml 
CD40 pg/mL 12 290 0.9 330+ Insulin Jlill/ml 
CD40 Ligand pg/mL 92 121 0.4 283+ IP-10 pg/ml 
CRP Jlg/mL 0.53 0.54 0.9 0.5965 KC/GROa ng/ml 
EGF pg/ml 39 LOW 3.8 10.385 Leptin ng/ml 
Endothelin-1 pg/ml 67 LOW 1.8 37.615 LIF pg/ml 
Eo tax in pg/ml 12 594 1.6 379.5 Lymphotactin pg/ml 
Factor VII ng/ml 0.96 0.51 0.8 0.63 MCP-1 pg/ml 
FGF-9 ng/ml 0.99 LOW 1.0 LOW MCP-3 pg/ml 
FGF-basic ng/ml 0.58 LOW 0.9 0.6705 MCP-5 pg/ml 
Fibrinogen ug/ml 12 138 1.3 108 M-CSF ng/ml 
GCP-2 ng/ml 0.025 II 1.4 7.59 MDC pg/ml 
GM-CSF pg/ml 8.7 LOW 1.1 8.263 MIP-lu ng/ml 
GH ng/ml 4.2 3.1 0.2 15.9+ MIP-1~ pg/ml 
GST-u ng/ml 0.42 LOW 1.0 LOW MIP-ly ng/ml 
Haptoglobin Jlg/ml 0.64 136 4.0 33.85 MIP-2 pg/ml 
IFN-y pg/ml 68 225 3.3 LOW MIP-3~ ng/ml 
IgA Jlg/ml 1.9 146 1.1 130 MMP-9 ng/mL 
IL-10 pg/ml 109 333 1.8 182.5 Myoglobin ng/ml 


































































Table 5 (continued) 
Anal:~::teb Units LDD Cone. A Uninfeeted' Anal:~::te Units LDD Cone. A Uninfeeted 
IL-12p70 ng/ml 0.57 LOW 1.0 LOW RANTES pg/ml 48 3.8 0.1 LOW 
IL-17 ng/ml 0.15 LOW 1.0 LOW SCF pg/ml 75 LOW 1.4 54.21 
IL-18 ng/ml 0.67 2.0 2.0 0.9935 SGOT ~J.g/ml 1.9 28 1.3 22.4 
IL-Ia pg/ml 45 283 0.9 328.5 TIMP-1 ng/ml 0.18 6.7 4.1 1.625 
IL-lP ng/ml 0.45 0.36 1.1 0.337 Tissue Factor ng/ml 0.52 3.0 0.8 3.49 
IL-2 pg/ml 67 LOW 1.0 LOW TNF-a ng/ml 0.14 LOW 1.0 LOW 
IL-3 pg/ml 21 LOW 1.0 LOW TPO ng/ml 2.7 12 1.1 11 
IL-4 pg/ml 74 LOW 1.0 LOW VCAM-1 ng/mL 0.95 1,830 1.1 1650 
IL-5 ng/ml 0.19 0.12 1.1 0.1155 VEGF pg/ml 38 88 0.7 135.5 
IL-6 E!.\"ml 14 27 2.0 LOW vWF n!.\"ml 99 40 0.7 53.9 
• Serum was collected on day 4 after virus exposure. 
Cone. concentration. 
LDD least detectable dose. 
!:J. fold change compared to uninfected mice. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
c Average of two samples sent at separate times. 
+ Does not represent average of two samples due to new assays added between times of analysis of two samples. 
between analysis ofi.n. and i.p. mice. Importantly the new growth hormone and 
glutathione S-transferase assays had different specificities than previously. 
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The analytes with the greatest fold increase for each model were noted (Tables 
6 and 7). In order of greatest stimulation, CPV i.n. infection produced IL-6, MCP-5, 
MCP-1, tissue inhibitor of metalloproteinase (TIMP)-1 , and IL-l 0 while CPV i.p. 
infection resulted in strong stimulation ofiL-6, MCP-1, MCP-5, IL-10, and MCP-3 . In 
the VV i.n. model the cytokines IFN-y, IL-6, IP-10, myoglobin, and MCP-1 were 
greatly increased. Although no analytes demonstrated as large an increase in the VV 
i.p. model as in the other models, those with the highest induction were MCP-3, MCP-
1, IP-10, TIMP-1, and haptoglobin. 
In the Panomics assays, the sensitivities for MIG, IP-1 0, IL-5, and IL-6 were 
2000 pg/ml whereas the others were I 000 pg/ml. Those cytokines with a sensitivity of 
2000 pg/ml may not indicate as strong an induction as those with the I 000 pg/ml 
sensitivity. As the MAP tests were able to detect analytes at lower ranges, they were 
more useful in comparing the induction of cytokines in each model. Additionally, the 
Panomics and MAP assays did not test for the same panel of cytokines. Neither G-
CSF nor MIG were analyzed in the MAP panel and MCP-1 was not analyzed in the 
Panomics assay. 
Taking these discrepancies into consideration, the data from both tests seem to 
correlate well. The CPV i.n. model showed strong stimulation ofiL-6 and IL-10 in 
both data sets while RANTES was only slightly induced in both assays. RANTES was 
also only slightly increased in VV i.n. infection in both assays. However, IFN-y, IL-6, 
and IP-10 levels were greatly elevated in the VV i.n. model according to the MAP 
Table 6 




Anall'teb Unit LDD Cone. A Cone. A Avg. Uninfeeted 
Eo tax in pg/ml 12 1,830 4.8 2,000 5.3 379.5 
IL-10 pg/ml 109 3,360 18.4 3,950 21.6 182.5 
IL-11 pg/ml 87 1,180 13.5 244 2.8 LOW 
IL-6 pg/ml 14 5,970 431.0 1,440 104.0 LOW 
MCP-1 pg/ml 17 8,620 54.2 6,230 39.2 159 
MCP-3 pg/ml 31 3,040 12.3 3,040 12.3 246.5 
MCP-5 pg/ml 46 8,255 56.9 3,210 22.1 145 
MIP-!p pg/ml 78 991 12.8 531 6.8 LOW 
SCF pg/ml 75 479 8.8 89 1.6 54.21 
TIMP-1 n~ml 0.18 52 31.7 15 9.2 1.625 
' Serum was collected on day 6 after virus exposure for i.n. infected mice and day 4 
after virus exposure for i.p. infected mice. The i.n. infected mice received placebo 
treatment i.p. once a day for two days starting 24 h after virus exposure. 
Cone. concentration. 
LDD least detectable dose. 
!!. fold change compared to uninfected sample analyzed at the same time as infected 
sample. 
LOW values not determinable on the standard curve. 
b IL, interleukin; MCP, monocyte chemoattractant protein, MIP, macrophage 
inflammatory protein; SCF, stem cell factor; TIMP, tissue inhibitor of 
metalloproteinase. 
'Average from two samples analyzed at separate times. 
assay while the Panomics assay only indicated slight induction of them. The 
differences in IL-6 and IP-1 0 production are easily explained by the high range of 
detection for these cytokines in the Panomics assays. The IFN-y discrepancy may be 
due to variation between animals or differences in the assays. Although the mice in the 
i.n. models received a placebo treatment and the i.p. mice did not, this factor should not 
affect the data at this point. The objective was to merely obtain a qualitative view of 
cytokine induction for each model, not a comparison between models. 
34 
Table 7 
Analytes with greatest induction in VV infections' determined by MAP analysis of 
2ooled serum 
VVi.n. VVi.p. 
Anal~teb Unit LDD Cone. A Cone. A Avg. Uninfected 
Haptoglobin Jlg/ml 0.64 90 2.7 136 4.0 33.85 
IFN-y pglml 68 3,510 51.8 225 3.3 LOW 
IL-11 pglml 87 787 9.0 53 0.6 LOW 
IL-6 pglml 14 423 30.5 27 2.0 LOW 
IP-10 pglml 40 3,490 22.4 945 6.1 155.6 
MCP-1 pglml 17 3,270 20.6 1,020 6.4 159 
MCP-3 pglml 31 3,340 13.5 1,790 7.3 246.5 
MCP-5 pglml 46 1,160 8.0 549 3.8 145 
Myoglobin nglml 24 2,820 21.2 19 0.1 133 
TIMP-1 n~ml 0.18 32 19.9 6.7 4.1 1.625 
' Serum was collected on day 6 after virus exposure for i.n. infected mice and day 4 
after virus exposure for i.p. infected mice. The i.n. infected mice received placebo 
treatment i.p. once a day for two days starting 24 h after virus exposure 
Cone. concentration. 
LDD least detectable dose. 
D. fold change compared to uninfected sample analyzed at the same time as infected 
sample. 
LOW values not determinable on the standard curve. 
b IFN, interferon; IL, interleukin; IP, interferon-y inducible protein; MCP, monocyte 
chemoattractant protein; TIMP, tissue inhibitor ofmetalloproteinase. 
c Average from two samples analyzed at separate times. 
Based upon the results of the Panomics and MAP assays, four cytokines were 
selected for continued study: IFN-y, IL-6, IP-1 0, and MCP-1 . MCP-1 was chosen 
since it was strongly induced in all four models. IL-6 and IP-1 0 were selected owing to 
their strong induction in three and two of the models, respectively. Due to its well 
established role in antiviral immune responses, IFN-y was also included. Although, 
other factors were also highly induced (see Tables 6 and 7), these cytokines were 
selected to obtain an array of cytokines stimulated in all four models and to avoid 
35 
similarity in cytokine function. For example, MIG which was induced in the Panomics 
assay for the VVi.n. model, shares similar effects as IP-10 (Farber, 1997). 
Time-course of Cytokine Induction 
Serum was collected on days I , 3, and 5 after virus exposure for all the models 
except CPV i.n. in which it was also collected on day 7 after virus exposure. This 
schedule was used to obtain optimum cytokine levels prior to death, and yet ensure that 
enough mice remained alive to allow sufficient collection of serum. In most of the 
models, cytokine concentrations increased by day 3 p.i and continued increasing 
throughout the time studied (Figures 2-9). However, this was not true for CPV i.n. and 
VV i.p. infection models. During the CPV i.n. infection, IFN-y and IP-10 had a 
delayed induction while in the VV i.p. infections, IP-10 and MCP-1 were already 
elevated by day I p.i. Almost all the infection routes showed increasing cytokine 
concentrations over time. Cytokine levels remained fairly constant throughout the time 
studied during VV i.p. infection, however. 
Survival, Mean Body Weight, and Virus 
Titer Determinations 
During the infections where cytokine profiles were presented, other mice were 
held for death to assess other infection parameters. Antiviral treatments were given to 
determine the effects of cidofovir on these parameters. Cidofovir treatment 
significantly decreased the mortality in all four models studied (Table 8). The results 
do not indicate a difference in the mean day of death between cidofovir and placebo 
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Days After Virus Exposure 
Fig. 2. Time-course of!FN-y induction in serum ofCPV i.n. (A) and CPV i.p. (B) 
infected mice. •. i.n.; .A , i.p. Data points represent mean± SD (3-5 mice/group). 





























Days After Virus Exposure 
Fig. 3. Time-course of!FN-y induction in serum ofVV i.n. (A) and VV i.p. (B) 
infected mice. e , i.n.; +, i.p. Data points represent mean± SD (5-6 mice/group). 
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Days After Virus Exposure 
Fig. 4. Time-course of!L-6 induction in serum ofCPV i.n. (A) and CPV i.p. (B) 
infected mice. • . i.n.; ~. i.p. Data points represent mean± SO (3-7 mice/group). 




























Days After Virus Exposure 
Fig. 5. Time-course ofiL-6 induction in serum ofVV i.n. (A) and VV i.p. (B) infected 
mice. e, i.n.; +, i.p. Data points represent mean± SD (5-6 mice/group). The 
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Days After Virus Exposure 
Fig. 6. Time-course of IP-1 0 induction in serum of CPV i.n. (A) and CPV i.p. (B) 
infected mice. • . i.n.; -"· i.p. Data points represent mean± SO (5 mice/group). The 

























Days After Virus Exposure 
Fig. 7. Time-course ofiP-1 0 induction in serum ofVV i.n. (A) a td VV i.p. (B) 
infected mice. e, i.n.; +, i.p. Data points represent mean± SD (5 mice/group). The 
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Days After Virus Exposure 
Fig. 8. Time-course ofMCP-1 induction in serum ofCPV i.n. (A) and CPV i.p. (B) 
infected mice. • . i.n.; A, i.p. Data points represent mean± SD (4-5 mice/group). 




























Days After Virus Exposure 
Fig. 9. Time-course ofMCP-1 induction in serum ofVV i.n. (A) and VV i.p. (B) 
infected mice. e , i.n. ; +, i.p. Data points represent mean± SD (5 mice/group). The 
concentration for uninfected mice (5 mice) was 2.15 ±0.23logw pg/ml. 
Table 8 
Effects of cidofovir on survival and mean day of death of infected mice 
Model Treatment' Survivors/Total Mean Day of Death 
CPV i.n. Cidofovir 10110*** >21 


















Ol iO 5.9±3.5 
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' I 00 mglkg cidofovir or placebo given i.p. once a day for two days starting 24 h after 
virus exposure 
* P<0.05, ** P<O.Ol, *** P<O.OOI 
for three models could not be performed because of the absence of death or low 
mortality. In repeated experiments, cidofovir was least effective in the treatment of the 
VV i.p. infection. 
The efficacy of cidofovir was demonstrated by the reduction of virus titers in 
cidofovir treated mice in each model studied (Table 9). The CPV i.n. infection resulted 
in high titers in the lungs and snouts. Antiviral treatment of these mice significantly 
decreased virus titers in the lungs. On the other hand, during VV i.n. infection high 
titers were obtained in all the tissues examined. These titers were also reduced 
significantly by cidofovir. Mice infected with CPV i.p. or VV i.p. developed high 
titers in all tissues examined except the brains. Cidofovir treatment significantly 
decreased viral load in the spleens, livers, and lungs of the CPV i.p. mice and in the 
spleens, livers, lungs, and snouts of the mice infected with VV i.p. Based on viral 
distribution, the CPV and VV i.p. infections appeared to be systemic infections. The 
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Table 9 
Effects of cidofovir on virus titers in CPV and VV infected mice. 
Model Treatmentb 
Virus Titers in Organs ( log10 p.f.u.lg of tissue)• 
Brain S~leen Liver Lung Snout 
CPVi.n. Cidofovir <2.0 2.2±0.6 2.0±0.0 7.5±0.1** 7.6±0.5 
CPVi.n. Placebo 2.2±0.4 2.9±0.7 2.2±0.5 8.1±0.1 7.0±0.6 
CPVi.p. Cidofovir <2.0 2.3±0.7** 2.5±0.8** 3.6±0.5** 5.2±0.8 
CPVi.p. Placebo 2.4±0.7 7.8±0.5 7.9±0.3 7.3±0.6 6.0±0.9 
VVi.n. Cidofovir 3.1±0.8* 2.4±0.8* 2.4±0.7* 7.1±0.7* 7.1±0.5* 
VVi.n. Placebo 5.5±0.2 7.1±0.5 5.0±0.9 8.2±0.2 8.1±0.3 
VVi.p. Cidofovir <2.0 <2.0** <2.0** <2.0** 2.8±1.3** 
VVi.E. Placebo 2.6±0.8 5.6±0.9 5.8±0.3 6.0±0.4 6.5±0.9 
• Mean± SD (4-6 mice/group) determined on day 6 after virus exposure. 
b I 00 mglkg cidofovir or placebo given i.p. once a day for two days starting 24 h after 
virus exposure 
* P<0.05, ** P<O.Ol. 
VV i.n. model is also a systemic infection with high titers throughout the host while 
CPV i.n. infection only affected the respiratory tract. 
During the infections the mice lost weight (Figures 10 and II), which is a 
measure of morbidity. Even the cidofovir treated mice lost weight before recovering. 
The data for the VV i.n. placebo treated mice indicate a rapid increase at day 7 p.i. 
which reflects the sicker mice dying off. 
Effects of Antiviral Treatment on 
Cytokine Concentrations 
As part of the antiviral analyses, treatments with cidofovir were done during 
infections with CPV and VV to determine drug effects on cytokine production. Based 
on the above time-course results, serum was collected on day 5 p.i . except for the CPV 
i.n. model in which it was collected on day 7 p.i . Although some cytokines were 
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Days After Virus Exposure 
Fig. 10. Mean body weight of treated CPV i.n (A) and CPV i.p. (B) infected mice. 
Mice were treated once a day i.p. for two days with cidofovir (I 00 mg/kg) or saline 
starting 24 h after virus exposure. • , CPV i.n. cidofovir treated; D, CPV i.n. placebo 
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Days After Virus Exposure 
Fig. II. Mean body weight of treated VV i.n (A) and VV i.p. (B) infected mice. Mice 
were treated once a day i.p. for two days with cidofovir (I 00 mg/kg) or saline starting 
24 h after virus exposure. +, VV i.n. cidofovir treated;<>, VV i.n. placebo treated; T , 
VV i.p. cidofovir treated; 'V , VV i.p. placebo treated. The rapid increase on day 7 for 
VV i.n. placebo treated mice is the result of the sicker mice dying. 
cidofovir to provide a beneficial effect and for maximum cytokine induction. 
Moreover, by taking most of the samples on the same day it allowed for the same 
sample to be used in multiple assays thus reducing cost and increasing efficiency. 
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Antiviral treatment resulted in significant reductions of cytokine concentrations 
in most models (Figures 12-15). Cidofovir treatment significantly reduced IFN-y, IL-
6, and MCP-1 in the CPV i.n. model; IL-6 and MCP-1 in the CPV i.p. model; IFN-y, 
IL-6, IP-10, and MCP-1 in the VV i.n. model; and IFN-y in the VV i.p. model. 
However, treatment did not significantly affect IP-10 in the CPV i.n. model; IFN-y and 
IP-10 in the CPV i.p. model; or IL-6, IP-10, and MCP-1 in the VV i.p. model. 
When taking into account variation, the MAP analysis shows similar effects of 
cidofovir as the ELISA kits (Tables I 0-13) for the respective assays. The IFN-y and 
IL-6 concentrations, however, seem consistently lower in the MAP tests compared to 
the ELISA assays. The only considerable difference in the MAP data is the effects of 
cidofovir on MCP-1 during CPV i.p. infections. As the results for the two assays were 
determined using different mice, perhaps the samples used in the MAP analysis 
included an extreme value. Since the serum is pooled the effects of such a value would 
not be discernible. Other factors were also reduced by cidofovir treatment (Tables 14 
and 15). Treatment had a strong affect on IL-6, IL-10, IL-17, IL-l!, and IFN-y in CPV 
i.n. infections. IL-6, myoglobin, IL-17, IL-l 0, and IL-12p70 were decreased in 
cidofovir treated CPV i.p. infected mice. Cidofovir treatment resulted in reductions IL-
6, IL-l!, MCP-1, IFN-y, and growth hormone (GH) in VV i.n. infected mice and GH, 
myoglobin, IP-10, TNF-a, and IFN-y in VV i.p. infections. Although the ELISA 
results indicate no significant effects of cidofovir on IP-1 0 in VV i.p. infections it must 
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Fig. 12. Effects of cidofovir on IFN-y induction in CPV (A) and VV (B) i.n. and i.p. 
infections. Mice were treated once a day i.p. for two days with cidofovir (! 00 mg!kg) 
or placebo starting 24 h after virus exposure. Serum was collected on day 5 after virus 
exposure except for CPV i.n. infections in which it was collected on day 7. There were 
4-6 mice/group. ** P<O.Ol , *** P<O.OO!. 
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~ i.n. cidofovir 
~ i.n. placebo 
D i.p. cidofovir 
"E .... • i.p. placebo Cl c. 0 Ci D Uninfected 0 ...J 
Fig. 13. Effects of cidofovir on IL-6 induction in CPV (A) and VV (B) i.n. and i.p. 
infections. Mice were treated once a day i.p. for two days with cidofovir (I 00 mg/kg) 
or placebo starting 24 h after virus exposure. Serum was collected on day 5 after virus 
exposure except for CPV i.n. infections in which it was collected on day 7. There were 
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i.p. cidofovir 
• i.p. placebo D Uninfected 
B 
Fig. 14. Effects ofcidofovir on IP-10 induction in CPV {A) and VV (B) i.n. and i.p. 
infections. Mice were treated once a day i.p. for two days with cidofovir (I 00 mg/kg) 
or placebo starting 24 h after virus exposure. Serum was collected on day 5 after virus 
exposure except for CPV i.n. infections in which it was collected on day 7. There were 
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~ i.n. placebo 
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• i.p. placebo D Uninfected 
Fig. 15. Effects of cidofovir on MCP-1 induction in CPV (A) and VV (B) i.n. and i.p. 
infections. Mice were treated once a day i.p. for two days with cidofovir (I 00 mglkg) 
or placebo starting 24 h after virus exposure. Serum was collected on day 5 after virus 
exposure except for CPV i.n. infections in which it was collected on day 7. There were 
5-6 mice/group. ** P<O.Oi, *** P<O.OOI. 
Table 10 
Anal~e profiles of treated mice infected with CPV i.n." determined from MAP anal;rsis of pooled serum 
Anal;rte6 Units LDD Cidofovir Placebo Anal:~:te Units LDD Cidofovir Placebo 
ApoA1 f!g/ml 10 118 71 IL-7 ng/ml 0.31 0.03 1 0.12 
CD40 pg/ml 12 382 1,270 Insulin f!lU/ml 2.0 3.9 1.2 
CD40 Ligand pg/ml 92 42 52 IP-10 pg/m1 40 129 1,580 
CRP f!g/ml 0.53 0.39 0.16 KC/GROa ng/m1 0.17 0.039 0.12 
EGF pg/ml 39 25 7.0 Leptin ng/m1 0.096 0.41 1.4 
Endothe1in-1 pg/m1 67 23 21 LIF pg/m1 44 258 1,380 
Eo tax in pg/m1 12 2,170 2,120 Lyrnphotactin pg/m1 85 93 735 
Factor VII ng/ml 0.96 0.97 0.26 MCP-1 pg/m1 17 774 3,460 
FGF-9 ng/ml 0.99 LOW 5.2 MCP-3 pg/ml 31 350 2,970 
FGF-basic ng/ml 0.58 1.5 1.6 MCP-5 pg/ml 46 337 >6,260 
Fibrinogen f!g/ml 12 167 202 M-CSF ng/ml O.ot8 3.3 3.7 
GCP-2 ng/ml 0.025 13 7.5 MDC pg/ml 22 498 703 
GM-CSF pg/ml 8.7 LOW 7.8 MIP-1a ng/ml 0.23 0.17 LOW 
GH ng/ml 4.2 13 71 MIP-1~ pg/m1 78 378 250 
GST-a ng/ml 0.42 LOW LOW MIP-1y ng/m1 0.074 34 >694 
Haptoglobin f!g/ml 0.64 149 128 MIP-2 pg/m1 7.2 LOW 14 
IFN-y pg/ml 68 26 639 MIP-3~ ng/m1 0.47 0.38 0.27 
lgA f!g/m1 1.9 122 46 MMP-9 ng/m1 10 38 41 
IL-10 pg/ml 109 147 7,670 Myoglobin ng/m1 24 763 2,010 
IL-11 pg/m1 87 35 896 OSM ng/m1 0.13 LOW 0.21 
Table I 0 (continued) 
Anall:te Units LDD Cidofovir Placebo Anall:te Units LDD Cidofovir Placebo 
IL-12p70 ng/ml 0.57 LOW 1.4 RANTES pg/ml 48 7.4 98 
IL-17 ng/ml 0.15 0.0076 0.20 SCF pg/ml 75 74 331 
IL-18 ng/ml 0.67 1.9 0.82 SGOT flg/ml 1.9 27 9.5 
IL-Ia pg/ml 45 207 304 TIMP-1 ng/ml 0.18 4.5 42 
IL-IP ng/ml 0.45 0.21 0.12 Tissue Factor ng/ml 0.52 2.3 0.97 
IL-2 pg/ml 67 LOW 177 TNF-u ng/ml 0.14 0.039 0.23 
IL-3 pg/ml 21 LOW 22 TPO ng/ml 2.7 7.3 2.5 
IL-4 pg/ml 74 LOW 159 VCAM-1 ng/ml 0.95 1,470 758 
IL-5 ng/ml 0.19 0.15 0.063 VEGF pg/ml 38 181 456 
IL-6 pg/ml 14 80 7,260 vWF ng/ml 99 28 50 
• Mice treated i.p. with cidofovir (100 mglkg) or placebo once a day for two days starting 24 h p.i. Serum was collected on day 7 
after virus exposure from 5 mice/group. 
LDD least detectable dose. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
Table II 
Anal~e profiles of treated mice infected with CPV i.p.' determined from MAP analz:sis of pooled serum 
Anal~te6 Units LDD Cidofovir Placebo Anal~te Units LDD Cidofovir Placebo 
ApoAI !!g/ml 10 108 110 IL-7 ng/ml 0.31 0.12 0.27 
CD40 pg/ml 12 437 2,140 Insulin !!IU/ml 2.0 3.7 1.8 
CD40 Ligand pg/ml 92 22 92 IP-10 pg/ml 40 272 420 
CRP !!g/ml 0.53 0.35 0.043 KC/GROa ng/ml 0.17 0.18 2.0 
EGF pg/ml 39 25 LOW Leptin ng/ml 0.096 0.26 0.54 
Endothelin-1 pg/ml 67 45 14 LIF pg/ml 44 265 3,240 
Eo tax in pg/ml 12 1,480 3,360 Lymphotactin pg/ml 85 260 407 
Factor VII ng/ml 0.96 1.1 0.48 MCP-1 pg/ml 17 2,310 3,260 
FGF-9 ng/ml 0.99 0.94 11 MCP-3 pg/ml 31 1,190 6,380 
FGF-basic ng/ml 0.58 1.7 3.9 MCP-5 pg/m1 46 832 >6,260 
Fibrinogen !!g/ml 12 161 214 M-CSF ng/ml O.ot8 3.9 4.8 
GCP-2 ng/ml 0.025 II 6.1 MDC pg/ml 22 451 1,030 
GM-CSF pg/ml 8.7 2.1 15 MIP-1a ng/ml 0.23 0.12 0.059 
GH ng/ml 4.2 31 60 MIP-Ip pg/ml 78 571 453 
GST-a ng/ml 0.42 LOW LOW MIP-1y ng/ml 0.074 45 >694 
Haptoglobin 11g/ml 0.64 114 128 MIP-2 pg/ml 7.2 11 101 
IFN-y pg/ml 68 80 203 MIP-3P ng/ml 0.47 0.31 0.24 
lgA !!g/ml 1.9 67 49 MMP-9 ng/ml 10 61 91 
IL-10 pg/ml 109 943 36,600 Myoglobin ng/ml 24 264 >18,175 
IL-11 pg/ml 87 100 880 OSM ng/ml 0.13 0.18 0.38 
Table 11 (continued) 
Anal~te Units LDD Cidofovir Placebo Anal~te Units LDD Cidofovir Placebo 
IL-12p70 ng/ml 0.57 0.095 2.4 RANTES pg/ml 48 24 150 
IL-17 ng/ml 0.15 0.010 0.41 SCF pg/ml 75 171 576 
IL-18 ng/ml 0.67 1.6 1.7 SGOT f.Lg/ml 1.9 24 7.1 
IL-l a pg/ml 45 235 219 TIMP-1 ng/ml 0.18 6.6 58 
IL-l~ ng/m1 0.45 0.28 0.054 Tissue Factor ng/ml 0.52 2.6 0.97 
IL-2 pg/ml 67 29 355 TNF-n ng/ml 0.14 0.23 0.40 
IL-3 pg/ml 21 LOW 47 TPO ng/ml 2.7 8.0 2.7 
IL-4 pg/ml 74 LOW 259 VCAM-1 ng/ml 0.95 1,540 753 
IL-5 ng/ml 0.19 0.42 0.086 VEGF pg/ml 38 293 857 
IL-6 pg/ml 14 73 17,400 vWF ng/ml 99 24 54 
'Mice treated i.p. with cidofovir (1 00 mglkg) or placebo once a day for two days starting 24 h p.i. Serum was collected on day 5 
after virus exposure from 4-5 mice/group. 
LDD least detectable dose. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
Table 12 
AnalY!e ~rofiles of treated mice infected with VV i.n.' determined from MAP anal;rsis of~ooled serum 
Anal~te6 Units LDD Cidofovir Placebo Anal~te Units LDD Cidofovir Placebo 
ApoAI !lg/ml 10 91 102 IL-7 ng/ml 0.31 0.047 0.13 
CD40 pg/ml 12 582 1,140 Insulin !iiU/ml 2.0 4.2 5.7 
CD40 Ligand pg/ml 92 176 339 IP-10 pg/ml 40 286 1,830 
CRP !lg/ml 0.53 0.33 0.25 KC/GROa ng/ml 0.17 LOW 0.41 
EGF pg/ml 39 23 38 Leptin ng/ml 0.096 0.40 0.76 
Endothelin-1 pg/ml 67 36 28 LIF pg/ml 44 304 528 
Eo tax in pg/ml 12 544 1,1 40 Lymphotactin pg/ml 85 142 330 
Factor VII ng/ml 0.96 1.1 1.2 MCP-1 pg/ml 17 108 1,820 
FGF-9 ng/ml 0.99 LOW 2.5 MCP-3 pg/ml 31 290 2,970 
FGF-basic ng/ml 0.58 2.0 1.8 MCP-5 pg/ml 46 217 1,140 
Fibrinogen !lglml 12 122 199 M-CSF ng/ml 0.018 3.9 3.9 
GCP-2 ng/ml 0.025 II 8.5 MDC pg/ml 22 473 461 
GM-CSF pg/ml 8.7 LOW LOW MIP-la ng/ml 0.23 0.23 0.25 
GH ng/ml 4.2 4.1 49 MIP-1~ pg/ml 78 144 365 
GST-a ng/ml 0.42 LOW LOW MIP-Iy ng/ml 0.074 15 38 
Haptoglobin !lglml 0.64 121 156 MIP-2 pg/ml 7.2 7.4 26 
IFN-y pg/ml 68 102 1,690 MIP-3~ ng/ml 0.47 0.35 0.20 
IgA !lglml 1.9 122 103 MMP-9 ng/ml 10 48 46 
IL-10 pg/ml 109 538 1,080 Myoglobin ng/ml 24 305 1,010 
IL-11 pg/ml 87 21 522 OSM ng!ml 0.13 0.020 0.17 
Table 12 (continued) 
Anal)::te Units LDD Cidofovir Placebo Anal)::te Units 
IL-12p70 ng/ml 0.57 LOW 0.28 RANTES pg/ml 
IL-17 ng/ml 0.15 0.010 0.036 SCF pg/ml 
IL-18 ng/ml 0.67 1.7 4.0 SGOT flg/ml 
IL-Ia pg/ml 45 172 292 TIMP-1 ng/ml 
IL-IP ng/ml 0.45 0.17 0.38 Tissue Factor ng/ml 
IL-2 pg/ml 67 LOW 73 TNF-a ng/ml 
IL-3 pg/ml 21 LOW 2.5 TPO ng/ml 
IL-4 pg/ml 74 LOW 55 VCAM-1 ng/ml 
IL-5 ng/ml 0.19 0.26 0.21 VEGF pg/ml 
IL-6 pg/ml 14 LOW 464 vWF ng/ml 
• Mice treated i.p. with cidofovir (100 mg/kg) or placebo once a day for two days starting 24 h p.i. 
after virus exposure from 5 mice/group. 
LDD least detectable dose. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
LDD Cidofovir Placebo 
48 LOW 62 
75 43 !51 
1.9 18 17 
0.18 3.5 20 
0.52 2.7 3.5 
0.14 0.033 0.28 
2.7 7.1 8.1 
0.95 1,670 1,440 
38 168 322 
99 22 63 




Analz:!e J?TOfiles of treated mice infected with VV i.J?.' determined from MAP analysis ofEooled serum 
Anal;):'te6 Units LDD Cidofovir Placebo Anal;):'te Units LDD Cidofovir Placebo 
ApoA1 !tg/ml 10 115 89 IL-7 ng/ml 0.31 0.063 0.052 
CD40 pg/ml 12 528 680 Insulin !tiU/ml 2.0 4.5 5.5 
CD40 Ligand pg/ml 92 176 311 IP-10 pg/ml 40 331 1,140 
CRP !tg/ml 0.53 1.3 0.31 KC/GROu ng/ml 0.17 LOW LOW 
EGF pg/ml 39 32 28 Leptin ng/ml 0.096 0.13 0.18 
Endothelin-1 pg/ml 67 28 20 LIF pg/ml 44 211 215 
Eo tax in pg/m1 12 715 653 Lymphotactin pg/ml 85 173 201 
Factor VII ng/ml 0.96 0.92 0.94 MCP-1 pg/ml 17 916 1,170 
FGF-9 ng/ml 0.99 0.65 1.1 MCP-3 pg/ml 31 1,810 2,380 
FGF-basic ng/ml 0.58 1.9 1.6 MCP-5 pg/ml 46 730 523 
Fibrinogen !tg/ml 12 196 133 M-CSF ng/ml O.ot8 3.4 3.6 
GCP-2 ng/ml 0.025 14 13 MDC pg/ml 22 406 420 
GM-CSF pg/ml 8.7 1.3 LOW MIP-1u ng/ml 0.23 0.17 0.21 
GH ng/ml 4.2 4.2 47 MIP-1P pg/ml 78 167 220 
GST-u ng/ml 0.42 LOW LOW MIP-Iy ng/m1 0.074 29 24 
Haptoglobin !tg/ml 0.64 200 138 MIP-2 pg/ml 7.2 18 35 
IFN-y pg/m1 68 52 144 MIP-3p ng/ml 0.47 0.18 0.20 
IgA !tg/ml 1.9 161 110 MMP-9 ng/ml 10 78 67 
IL-10 pg/ml 109 347 893 Myoglobin ng/ml 24 235 2,230 
IL-11 pg/ml 87 93 124 OSM ng/m1 0.13 0.076 0.097 
Table 13 (continued) 
Anal~te Units LDD Cidofovir Placebo Anal~te Units LDD Cidofovir Placebo 
IL-12p70 ng/ml 0.57 LOW LOW RANTES pg/ml 48 36 32 
IL-17 ng/ml 0.15 0.018 0.021 SCF pg/ml 75 76 98 
IL-18 ng/ml 0.67 3.2 4.1 SGOT f.!g/ml 1.9 35 20 
IL-1u pg/m1 45 309 377 TIMP-1 ng/ml 0.18 12 16 
IL-l~ ng/ml 0.45 0.22 0.30 Tissue Factor ng/ml 0.52 2.8 3.0 
IL-2 pg/ml 67 13 LOW TNF-u ng/ml 0.14 0.061 0.20 
IL-3 pg/ml 21 LOW LOW TPO ng/ml 2.7 8.1 7.4 
IL-4 pg/ml 74 LOW LOW VCAM-1 ng/ml 0.95 1,720 2,300 
IL-5 ng/ml 0.19 0.27 0.22 VEGF pg/ml 38 191 264 
IL-6 pg!ml 14 51 73 vWF ng/ml 99 52 50 
• Mice treated i.p. with cidofovir (100 mglkg) or placebo once a day for two days starting 24 h p.i. Serum was collected on day 5 
after virus exposure from 3-4 mice/group. 
LDD least detectable dose. 
LOW values not determinable on the standard curve. 
b Analyte abbreviations same as Table 2. 
61 
Table 14 
Analytes greatly affected by cidofovir treatment in CPV infections• detennined by 
MAP anal}::sis ofEooled serum 
CPVi.n. CPVi.p. 
Anal:!:teb Units LDD Cidofovir Placebo Cidofovir Placebo 
IFN-y pglml 68 26 639 80 203 
IL-10 pglml 109 147 7,670 943 36,600 
IL-11 pglml 87 35 896 100 880 
IL-12p70 nglml 0.57 LOW 1.4 0.095 2.4 
IL-17 nglml 0.15 0.0076 0.20 0.010 0.41 
IL-6 pglml 14 80 7,260 73 17,400 
LIF pglml 44 258 1,380 265 3,240 
MCP-5 pglml 46 337 >6,260 832 >6,260 
MlP-ly nglml 0.074 34 >694 45 >694 
Mz:oglobin n~ml 24 763 2,010 264 >18,175 
• Mice treated i.p. with cidofovir (I 00 mglkg) or placebo once a day for two days 
starting 24 h p.i. Serum was collected from 4-5 mice/group on day 7 after virus 
exposure for i.n. infected mice and day 5 after virus exposure for i.p. infected mice. 
LDD least detectable dose. 
LOW values not detenninable on standard curve. 
b IFN, interferon; IL, interleukin; LIF, leukemia inhibitory factor; MCP, monocyte 
chemoattractant protein; MlP, macrophage inflammatory protein. 
be kept in mind that the differences suggested by the MAP data are only based on 
pooled serum and do not take into account variation between samples. 
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Table 15 
Analytes greatly affected by cidofovir treatment in VV infections' determined by MAP 
anal~sis of QOOled serum 
VVi.n. VVi.p. 
Anall:teb Units LDD Cidofovir Placebo Cidofovir Placebo 
GH nglml 4.2 4.1 49 4.2 47 
IFN-y pglml 68 102 1,690 52 144 
IL-10 pglml 109 538 1,080 347 893 
IL-11 pglml 87 21 522 93 124 
IL-6 pglml 14 LOW 464 51 73 
IP-10 pglml 40 286 1,830 331 1,140 
MCP-1 pglml 17 108 1,820 916 1,170 
MCP-3 pglml 31 290 2,970 1,810 2,380 
Myoglobin nglml 24 305 1,010 235 2,230 
TNF-u ng,'ml 0.14 0.033 0.28 0.061 0.20 
'Mice treated i.p. with cidofovir (100 mglkg) or placebo once a day for two days 
starting 24 h p.i. Serum was collected from 3-5 mice/group on day 5 after virus 
exposure. 
LDD least detectable dose. 
LOW values not determinable on standard curve. 
b GH, growth hormone; IFN, interferon; IL, interleukin; IP, interferon-y inducible 
protein; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor. 
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DISCUSSION 
Cidofovir is an effective antiviral compound for CPV and VV infections. It 
significantly increased the number of survivors in all models. CPV and VV i.n. 
infections resulted in different tissues being affected. CPV i.n. infection resulted in 
high titers mainly in the lung and snout while VV i.n. infection resulted in high titers 
throughout the body. These differences in viral distribution in CPV and VV i.n. 
infections have been previously documented (Smee et al. , 200la). The i.p. infections 
resulted in high titers throughout the body excluding the brain. Cidofovir treatment 
significantly reduced virus titers in all models studied demonstrating its antiviral 
properties. Although cidofovir provided antiviral effects for the VV i.p. infected 
animals, the effects were not as great as seen in the other models as indicated by the 
number of survivors and mean day of death. As infection in this model initiates a very 
rapid onset of disease and death, perhaps there may not be sufficient time for the 
effects of cidofovir to be as strong as in the other models. The ability of cidofovir to 
reduce mortality and virus titers in the CPV and VV i.n. models has been previously 
demonstrated (Bray et al., 2000; Smee et al., 200la; Smee et al., 200lb; Quenelle et al., 
2003). To my knowledge, the effects of cidofovir on i.p. infections in 
immunocompetent mice with these viruses have not been previously reported. Though, 
Quenelle et al. (2003) did document the effects of cidofovir on CPV and VV i.p. 
infected severe combined immunodeficient mice. Cidofovir treated mice lost weight 
during the course of infection. This observation corresponds with previous findings 
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indicating weight loss and thus morbidity in cidofovir treated mice (Bray et al., 2000; 
Smee et al., 2001 a; Smee et al., 2001 b). 
The data demonstrate distinct differences in the pathogenesis of infection in the 
four mouse models studied. Based on viral distribution, the CPV i.n . model seemed to 
be mainly a respiratory infection while the other models were systemic infections. The 
CPV i.n. model also had a unique pattern of cytokine induction. IL-6 and MCP-1 
appear to be the first components of the cytokine response followed by IFN-y and lP-
10. The delayed induction of the two cytokines in the CPV i.n. model correlates well 
with the later mean day of death to indicate that this infection takes a longer time to 
establish. The placebo CPV i.n. animals had drastically elevated levels ofiFN-y, IL-6, 
and MCP-1 . Antiviral treatment significantly reduced these concentrations, though 
IFN-y concentrations were still highly elevated. IL-6 levels also were elevated after 
treatment. As some cytokines remained elevated after treatment, it could be that they 
provided some antiviral functions 7 days after infection. The need for these cytokines 
could be explained by the fact that the cidofovir treated groups infected with CPV i.n. 
show some viral clearance in the lungs but not the snouts at day 6 p.i . and the loss of 
weight was still occurring at this time. 
During the CPV i.p. infection, the concentrations of all cytokines continued to 
increase throughout infection. IFN-y, IL-6, and MCP-1 concentrations were stimulated 
to a great extent. However, treatment only significantly reduced IL-6 and MCP-1 
levels. Once again IP-1 0 and IFN-y concentrations remained elevated. Almost all 
infected organs except the snouts showed viral clearance by day 6 indicating that the 
animals have not completely recovered from infection at this time. 
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In the VV i.n. model, it appears that all four cytokines are also important 
components in the immune response. Infection by the VV i.n. route markedly 
stimulated IFN-y, IL-6, and IP-10. Induction of these cytokines was observed by day 3 
and continued to increase by day 5. Cidofovir treatment significantly lowered all four 
cytokines concentrations in this model with IFN-y and IP-10 remaining high on day 5 
p.i . after treatment. At this time-point these mice were still recovering from the 
infection as the cidofovir treated group had maximum weight loss, and the lungs and 
snouts still had elevated titers. 
The VV i.p. model is a systemic infection. The immune system responded 
rapidly as IP-10 and MCP-1 were elevated by day I p.i. Interestingly, the 
concentrations of the cytokines appeared to remain fairly constant throughout the 
infection. Both IFN-y and IL-6 showed large amounts of variation on day I, but at day 
3 and 5 the concentrations were similar. This pattern of induction was not observed in 
the other models. The early induction of cytokines in this model correlates well with 
the rapidity and severity of this infection model. The fairly constant production of 
cytokines may imply that this model induces the strongest response possible in these 
mice at the beginning of infection after which they were not capable of mounting any 
further effects. During this infection model, highly elevated concentrations ofiFN-y 
and IP-1 0 were reached, though antiviral treatment only significantly reduced IFN-y 
levels. IP-1 0 and IFN-y concentrations appeared elevated even after cidofovir 
treatment. Even though treated animals show viral clearance by day 6 there was still 
morbidity at day 5 p.i. as these animals were only beginning to recover their body 
weight at this time. 
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To use these cytokines as measures of infection, each model must be considered 
separately. For a particular model, the cytokine would need to be selected based on 
strong induction during infection and significant reduction during antiviral treatment. 
For the CPV i.n. model suitable candidates would be IFN-y, IL-6, or MCP-1 . The 
delayed induction ofiFN-y might render it a less ideal marker of infection in this 
model though. IL-6 and MCP-1 could also be used as measures of infection for CPV 
i.p. Any of the four cytokines studied could be used for VV i.n. models. However, 
IFN-y or IL-6 would be the best choices as cidofovir treatment resulted in drastic 
reductions of these cytokines. The only potential marker of infection for VV i.p. would 
be IFN-y as this cytokine was the only one significantly affected by antiviral treatment. 
The MAP data also indicates other potential markers of infection as cidofovir treatment 
drastically reduced certain analyte levels, although the statistical significance of the 
affects of cidofovir on these factors would need to be determined. GH could 
potentially serve as a measure of infection for the VV infections while IL-l 0 could be a 
marker for CPV infections. During the i.p. infections myoglobin was greatly reduced 
and could be used in these models. The data also indicate that IL-11 may be useful as a 
measure of infection during i.n. infections. 
Infection via the i.n. route for both viruses showed some similarities. Both 
viruses drastically induced IFN-y and IL-6 but the chemokines that were stimulated are 
different: a strong MCP-1 response in CPV versus a strong IP-1 0 response in the VV 
model. There were not many similarities between the i.p. models. In all models IP-10 
and IFN-y remained elevated to some extent after treatment. lntl:restingly, infections 
with CPV either i.n. or i.p. resulted in very drastic inductions ofMCP-1 and IL-6 
compared to the VV infections. In order to understand the implications of these 
findings it is necessary to consider the functions of these cytokines. 
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IFN-r has a well established role in the antiviral immune response which has 
previously been discussed. Its role in inducing the antiviral state is an important factor 
in resolving viral infections. IFN-r is also involved in inducing NO synthase and 
activating NK cell activity (De Maeyer and De Maeyer-Guignard, 1998; Biron and 
Sen, 200 I). These responses are also valuable in overcoming viral infections. 
Inducible NO synthase produces reactive NO intermediates which inhibit VV 
replication and protein synthesis (Biron and Sen, 2001). In addition to these functions, 
IFN-r is also important in the polarization of the T helper response. Thl cells produce 
IFN-r which inhibits Th2 differentiation (De Maeyer and De Maeyer-Guignard, 1998). 
A Thl response is conducive to recovery from viral infections. Its importance in 
responding to viral infections is illustrated by a number of studies showing increased 
susceptibility when IFN-r does not function. For example, infection of mice lacking 
type II IFN resulted in increased susceptibility to VV infections with increased viral 
titers and mortality (Muller et a!., 1994). This cytokine plays a leading role in antiviral 
immune response. 
The cytokine IL-6 has many different functions. It is involved in antibody 
production, differentiation of CTLs, the inflammatory response, the fever response, the 
mucosal immune response, the acute-phase response, and haematopoiesis (Hirano, 
1998; Biron and Sen, 2001). IL-6 also stimulates secretion of hormones including 
adrenocorticotrophic hormone, growth hormone, luteinizing hormone, and prolactin 
(Hirano, 1998). Its role in mucosal immunity is important in viral challenges to the 
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mucosa. Mice with a disrupted IL-6 gene show a reduction in immunoglobulin A 
plasma cells in the small intestine, mesenteric lymph nodes, and lungs, as well as an 
inability to produce mucosal antibody secreting cells after i.n infection with rVV 
encoding the influenza hemagglutinin protein (Ramsay eta!., 1994). However, when 
rVV encoding the murine IL-6 gene along with hemagglutinin was introduced i.n., 
these mice were capable of mounting a mucosal antibody response (Ramsay et a!., 
1994). IL-6 is also a regulator of the acute-phase response. The acute-phase reaction 
is an important early response system to pathogens. During this response, hepatocytes 
produce proteins which are capable of activating the complement cascade or 
opsonizing pathogens. Without this cytokine, mice exhibited a lower acute-phase 
response to Listeria monocytogenes, a Gram-positive bacterium (Kopf eta!., 1994). 
IL-6 induces many different acute-phase proteins: a 1-acid glycoprotein, a1-
antichymotrypsin, a 1-antitrypsin, C-reactive protein, fibrinogen, haptoglobin, and 
serum amyloid A (Hirano, 1998). IL-6 has been implicated in playing a role in the 
antiviral immune responses. In vitro infections with different viruses induced IL-6 
production to varying degrees with some cells secreting high levels ofiL-6 despite 
pathological changes (Sehgal et a!., 1988). Furthermore, IL-6 deficient mice have 
increased susceptibility to VV WR with a diminished CTL respoase (Kopf et a!., 
1994). Although IL-6 and other proinflammatory cytokines induce glucocorticoid 
hormones to inhibit damage by high concentrations of cytokines, mice with high 
systemic levels ofiL-6 and TNF-a from viral infection still had liver damage and 
necrosis (Biron and Sen, 2001). Although the many functions ofiL-6 may make it 
difficult to evaluate its role, it is clearly an important mediator ofthe antiviral response. 
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IP-1 0 is a CXC chemokine. Unlike other CXC chemokines, IP-1 0 does not 
attract neutrophils but monocytes, T lymphocytes, and NK cells (Wuyts et a!., 1998). 
Its functions include increasing T cell adhesion to endothelial cells and adhesion 
molecules, activation and enhancement ofNK cell activity, inhibition of angiogenesis, 
inhibition of hematopoietic progenitors, and inhibition of tumor growth (Farber, 1997; 
Wuyts et a!., 1998). Research has established a role for IP-1 0 in the resolution of viral 
infections. Using rVV expressing IP-1 0, Mahalingam et a!. (1999) demonstrated that 
athymic nude mice were able overcome infection with no recorded morbidity, lower 
viral titers, increased NK cell cytolytic activity, and increased mononuclear cell 
infiltration in the liver; however, higher doses of the rVV's only delayed mean time to 
death in these mice. Induction of!P-10 is dependent on interferons. IP-10 mRNA is 
induced by IFN-a/~ and IFN-y (Vanguri and Farber, 1990). Moreover, infection of 
IFN-y knockout mice with VV WR i.p. reduced IP-10 mRNA expression while 
infection of mice deficient in both type I and II interferon receptors resulted in no IP-1 0 
mRNA induction (Mahalingam and Karupiah, 2000). The antiviral effects of!P-10 are 
probably due in part to the induction of a Thl response. CXCR3, the receptor for IP-
10, was expressed at high levels on Thl cells (Bonecchi eta!., 1998; Sallusto eta!., 
1998). Additionally, Th I , but not Th2, cells were attracted to IP-1 0 (Bonecchi et a!., 
1998; Sallusto et a!., 1998; Siveke and Hamann, 1998). The antiviral effects of IP-1 0 
are also due to NK cells. IP-1 0 has also been shown to increase NK cell migration and 
cytolysis {Taub eta!., 1995). During the study by Mahalingam eta!. (1999), it was 
demonstrated that the enhanced antiviral response to rVV encoding IP-10 was 
dependent on NK cells as depletion of these effector cells resulted in significantly 
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higher titers in the rVV-IP-10 infected mice but did not effect control virus replication. 
The antiviral role of IP-1 0 is well established. 
MCP-1 is a CC chemokine. It is chemotactic for monocytes, basophils, T cells, 
and NK cells (Proost et al., 1998). It has been shown that MCP-1 also increases NK 
cell migration, and cytolysis (Taub et al., 1995). The influence MCP-1 has on Th 
response is debatable. Some suggest a role in Th2 polarization for MCP-1. Gu et al. 
(2000) demonstrated that T cells from MCP-1 deficient C57BV6 mice could produce 
normal levels ofThl cytokines IFN-y and IL-2 but only low levels ofTh2 cytokines 
IL-5 and IL-l 0. Comparing Leishmania major infections in BALB/c mice which 
respond to this pathogen with a Th2 response, MCP-1 deficient mice showed Jess 
footpad swelling and progressive lesions than wild type mice (Gu et al., 2000). In a 
separate study the presence ofMCP-1 indirectly promoted Th2 differentiation from 
nai've T cells through increased IL-4 production from T cells (Karpus et al., 1997). 
However, this view is contradicted by other research. Both Thl and Th2 cells 
expressed CCR2, the only known receptor for MCP-1, with higher levels of the 
receptor expressed on Th I cells (Bonecchi et al., 1998). Additionally, MCP-1 is 
chemotactic for both Th I and Th2 cells (Bonecchi et al., 1998). Another study showed 
that this capability to attract either Thl and Th2 cells depended on concentration: Thl 
cells responded to high doses ofMCP-1 while Th2 responded at low levels (Siveke and 
Hamann, 1998). This Thl versus Th2 debate is discussed in a review by Daly and 
Rollins (2003) who suggest that MCP-1 may have another undiscovered receptor, other 
ligands activate CCR2 to direct a Thl response, or MCP-1 stimulates a Th2 response in 
naive cells and chemotaxis of already differentiated Thl cells. The fact that VV and 
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CPV encode a chemokine binding protein that binds CC chemokines but not CXC or C 
chemokines also indicates the potential importance of this chemokine in poxvirus 
infections as this immunomodulator binds MCP-1 with high affinity (Alcami et al., 
1998). Through these effects MCP-1 can be important in the resolution ofviral 
infections. 
It is difficult to determine the specific effects these cytokines were having in 
these models as the cytokines are pleiotropic and these experiments were not designed 
to ascertain their functions. However, their roles in these models can be postulated. 
All four infections strongly induced IFN-y. This finding is not surprising due to its 
importance in the antiviral immune response. Since IFN-y, IP-1 0, and MCP-1 are all 
involved in enhancing migration and/or activity ofmacrophages and NK cells, these 
immune cells are probably involved in all the infections since combinations of these 
cytokines were observed in all models. Although a previous study demonstrated a 
strong macrophage response in the BAL ofBALB/c mice exposed to I 04 p.f.u . VV WR 
i.n., they observed only few NK cell infiltration (Reading and Smith, 2003a). 
However, only the cellular response in the lungs was evaluated. Thus NK cells could 
also be involved in mediating recovery from these infections. Given that both the i.n. 
models strongly induced IL-6, it may be that IL-6 is coordinating the mucosal immune 
response during these infections as the viruses are directly exposed to the mucosa of 
the respiratory tract. Although this function would be mediated by a Th2 response, 
which would be inhibited by the presence ofTh1 cytokine IFN-y, it is certainly in line 
with finding that BALB/c mice are predisposed to Th2 responses (Charles et al., 1999). 
Moreover, all of the models resulted in high viral titers in the lungs and snouts which 
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could require a mucosal antibody response to clear. However, as the other models 
result in systemic infections, IL-6 is probably affecting other responses. These effects 
would probably be inflammation and CTL differentiation. It is not clear what type of 
Th response is involved in these infections. As both CPV models produced high levels 
ofMCP-1 it could be surmised that this factor is mediating Thl effects which is 
supported by the presence of!FN-r also a Thl cytokine. However, the MAP and 
Panomics assays indicated strong induction ofiL-1 0, which inhibits the Th I response, 
in CPV i.n. and i.p. infections. The role of IL-6 in the acute-phase reaction in any of 
the models studied is also unclear. Two of the three acute-phase proteins included in 
the MAP analysis (C reactive protein and fibrinogen) showed only slight elevation at 
the time studied. However, haptoglobin, a late acute phase protein which binds free 
hemoglobin, was elevated about 3- to 4-fold in all models studied. This apparent 
elevation may simply have been the result of sampling and pooling the serum. The 
actual role of these cytokines would need to be verified through further experiments 
evaluating the cellular responses in these models. 
The influence of innate immunity on the outcome of the adaptive response has 
gained prominence in the past years. As the initial phases of the two infection routes 
examined in this study occurred in distinct areas of the body it is likely that different 
components of the innate immune response were stimulated. Studies examining these 
components have supported this view. Reading and Smith (2003a) showed that 
infection with VV by the i.n. route resulted in a strong initial response of macrophage 
but little neutrophil involvement; on the other hand, i.d. infection produced strong 
neutrophil and macrophage responses. In the infection models examined in this study 
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it is likely that similar patterns of innate immunity were involved. At the onset of 
infection, the i.n. routes most likely triggered strong macrophage responses while the 
i.p. infections probably stimulated strong macrophage and neutrophil responses. NK 
cells were probably involved in the early response to i.p. infections as well since the 
primary peripheral NK cell populations are located in the blood, spleen, and bone 
marrow and as these cells were activated after systemic challenge with viruses (Biron 
et a!., 1999). Because these innate immune cells produce a variety of cytokines, a 
differential response could easily have lead to distinct patterns of cytokine induction. 
Neutrophils release TNF-a; NK cells generate IFN-y and TNF-a, and macrophages can 
produce IL-6, IL-10, GM-CSF, IFN-a!p, TNF-a, IP-10, and MCP-1 as well as other 
cytokines (Guidotti and Chisari, 2001). TLRs are another component of the innate 
immune response that may have affected the pattern of cytokine induction in these 
models. The route of infection has been shown to influence different cytokine 
responses by TLRs. When CpG DNA, which activates TLR9, was administered by the 
i.n. or i.p. route it induced different patterns of cytokines. Mice treated i.n. with CpG 
DNA had higher levels ofRANTES and MIP-1P in BAL than i.p. dosed mice while 
mice given CpG DNA i.p. had high systemic levels ofiFN-y and TNF-u unlike mice 
given this factor i.n. (Rees et a!., 2005). The route of infection can clearly elicit a 
differential innate immune response which can in tum influence the outcome of the 
infection. 
Other studies also found that these cytokines were strongly induced by poxvirus 
infection which correlates with the findings of this study. IFN-y concentrations were 
increased in serum of humans vaccinated with VV by approximately 200 percent 
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(Rock et a!., 2004). When spleen cells immune to VV were re-stimulated with the 
virus they showed a delayed but rapid increase ofiFN-y with peak levels by 24 h p.i. 
(Carpenter et a!., 1994). IL-6 has been shown to be rapidly induced during poxvirus 
infections. Carpenter eta!. (1994) also demonstrated that these spleen cells produced 
IL-6 which peaked by 12 h p.i .. Additionally, VV WR infection of human fibroblasts 
stimulated IL-6 mRNA as early as 4 h p.i. with protein levels increasing by 48 h p.i. to 
about 2000 pg/ml (Rokita eta!., 1998). Amichay et al. (1996) noted IP-10 mRNA 
induction in BALB/c mice during VV WR i.p. infections. In another study, mice 
infected with VV WR 106 p.f.u. i.p. demonstrated high levels ofiP-10 mRNA on days 
3 and 6 p.i. in the uteri, ovaries, spleen and liver (Mahalingarn and Karupiah, 2000). In 
variola infections of monkeys, elevated concentrations ofiFN-y, IL-6, and MCP-1 
were observed (Jahrling et al., 2004). Reading and Smith (2003a) noted peak levels of 
IFN-y of about 2000 pg/ml and strong induction ofMCP-1 in BAL of mice infected i.n. 
with VV WR. Although their study found increased induction of these cytokines 
during infection, the concentrations did not reach those obtained in this study. These 
differences can be explained by the fact that Reading and Smith (2003a) studied the 
responses of these cytokines in the lung not in the serum, they used lower infectious 
doses, the process of collecting BAL resulted in dilution of the cytokines, and they 
stimulated less severe infections seeing as all mice in their study survived. 
Each cytokine studied has been associated with increased disease conditions. 
Increased IFN-y levels were found in patients with systemic lupus erythematosus and 
rheumatoid arthritis (Baccala et al., 2005). Furthermore, transgenic expression of this 
cytokine induced diabetes in normal mice (Baccala et a!., 2005). IL-6 has also been 
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associated with some autoimmune diseases. High concentrations ofiL-6 were found in 
patients with rheumatoid arthritis, systemic lupus erythematosus, and Crohn 's disease 
(Ishihara and Hirano, 2002). In addition to these findings, IL-6 deficient mice showed 
decreased insulin-dependent diabetes mellitus or experimental autoimmune 
encephalomyelitis (EAE) (a model of multiple sclerosis) occurrences in susceptible 
mouse models (Ishihara and Hirano, 2002). Elimination ofiP-10 also decreased EAE 
disease symptoms of susceptible mice (Tsunoda et al. , 2004). Reduction in IP-1 0 has 
also been associated with decreasing disease symptoms in at least one type of viral 
infection (Mahalingam et al., 2003). Deficiencies in MCP-1 or its receptor CCR2 
prevented EAE (Daly and Rollins, 2003). 
As these cytokines have been implicated in some disease pathologies, there is 
the possibility that modulating these cytokine could ameliorate symptoms. Depletion 
of IFN-y would be inadvisable, however, due to its central role in mediating viral 
resolution and many studies altering IFN-y levels demonstrated an increased 
susceptibility to viral infections. As proinflammatory cytokines have been associated 
with tissue damage, JL-6 may be a candidate for modulation. Eliminating IL-6, 
however, has also been proven to be detrimental to host recovery from VV infections. 
Since the pattern of cytokine induction for the CPV i.n. model may indicate that this 
cytokine is involved in initial responses to viral infection, perhaps altering IL-6 levels 
after this time period could improve recovery from infection. As IP-1 0 has also been 
implicated in tissue damage during viral infection and its concentrations were not 
affected by antiviral treatment perhaps reducing IP-1 0 levels may be beneficial. 
However, if the continued presence ofiP-10 is mediating immune effects its 
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modulation would have adverse effects. Likewise, ifMCP-1 is contributing to a Th2 
response, which is detrimental to the host in VV infections, depletion could potentially 
enhance recovery, but if on the contrary, it is assisting in NK and macrophage activity 
then decreasing MCP-1 concentrations could be detrimental. Once again, further 
studies would be required to elucidate which cytokine to modulate in a particular 
infection and at what time this should occur. 
Although this study shows distinct differences in the immune responses during 
CPV and VV infection models there is still much to be learned about these infections. 
With further research the immune responses and effects of cidofovir in poxvirus 
infections can be further established. As antiviral research continues there is the hope 
that the threat of smallpox will be completely eliminated due to the development of 
highly effective treatment measures. Perhaps one day pox viruses will only be viewed 
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